{"gene":"PRNP","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":2000,"finding":"NMR solution structure of human PrP(23-230) revealed a globular C-terminal domain (residues 125-228) containing three α-helices (144-154, 173-194, 200-228) and a short antiparallel β-sheet (128-131, 161-164), with an N-terminal flexibly disordered tail; local conformational states of helices 2 and 3 are influenced by N-terminal tail length.","method":"NMR spectroscopy (solution structure of recombinant full-length and truncated human PrP)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — high-resolution NMR structure with multiple constructs, foundational paper","pmids":["10618385"],"is_preprint":false},{"year":1989,"finding":"A missense mutation at PRNP codon 102 (Pro→Leu) is linked to Gerstmann-Sträussler syndrome, establishing that a pathogenic mutation in the prion protein gene causes inherited prion disease.","method":"Genetic linkage analysis in GSS pedigrees; DNA sequencing of PRNP","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — genetic linkage replicated across two independent pedigrees; foundational discovery","pmids":["2564168"],"is_preprint":false},{"year":1991,"finding":"Homozygosity at PRNP codon 129 (Met/Met or Val/Val) strongly predisposes to sporadic Creutzfeldt-Jakob disease, indicating that heterozygosity at this polymorphic site is protective, consistent with a mechanism requiring intermolecular PrP-PrP interaction during prion propagation.","method":"Case-control genotyping of codon 129 in sporadic CJD patients versus normal controls","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — large case-control study, subsequently replicated worldwide; mechanistic inference supported by protein-only hypothesis","pmids":["1677164"],"is_preprint":false},{"year":1992,"finding":"Fatal familial insomnia and a subtype of familial CJD are both linked to the same Asn178 mutation in PRNP, but the distinct disease phenotypes are determined by the codon 129 Met/Val polymorphism on the mutant allele: Met129-Asn178 segregates with FFI, Val129-Asn178 with familial CJD.","method":"Segregation analysis and PRNP sequencing/restriction analysis in multiple kindreds","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — mechanistic allelic dissection across 11 kindreds (15 FFI + 15 fCJD affected members), foundational","pmids":["1439789"],"is_preprint":false},{"year":1992,"finding":"Fatal familial insomnia is caused by a point mutation at PRNP codon 178 (Asp→Asn), producing a protease-resistant PrP isoform with a distinct fragment pattern from that of CJD, demonstrating that codon 178 mutation alters PrP conformation and disease phenotype.","method":"PRNP sequencing, proteinase K digestion + Western blot, restriction enzyme analysis, linkage analysis","journal":"The New England Journal of Medicine","confidence":"High","confidence_rationale":"Tier 1-2 — direct mutation identification with biochemical characterization, LOD score 3.4","pmids":["1346338"],"is_preprint":false},{"year":1991,"finding":"Insertions of 5, 7, or 8 extra octapeptide coding repeats in the PRNP gene (resulting in 10–13 total repeats) are associated with familial transmissible CJD, establishing that expansion of the octapeptide repeat region of PrP causes inherited prion disease.","method":"PRNP sequencing and family screening of confirmed neuropathologically and experimentally transmitted CJD cases","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — mutation-phenotype co-segregation with experimental transmission validation","pmids":["1683708"],"is_preprint":false},{"year":1996,"finding":"Both PrPC and PrPSc co-localize in caveolae-like detergent-insoluble membrane domains (CLDs/rafts) isolated from scrapie-infected neuroblastoma cells and Syrian hamster brain, supporting the hypothesis that PrPSc formation occurs within these cholesterol-rich membrane microdomains.","method":"Subcellular fractionation (Triton X-100 and detergent-free sonication), sucrose gradient flotation, sulfo-NHS-biotin cell-surface labeling, Western blot","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — two independent purification methods (detergent and detergent-free), confirmed in two species","pmids":["8962161"],"is_preprint":false},{"year":1996,"finding":"PrP transgenes lacking the N-terminal 26 or 49 amino-proximal residues fully restore susceptibility to scrapie, prion propagation, and PrPSc accumulation in PrP-knockout mice, demonstrating that the amino-proximal domain of PrPC is dispensable for conversion to PrPSc.","method":"Transgenic mouse inoculation with scrapie prions; Western blot for PrPSc accumulation; disease bioassay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic rescue experiment with multiple truncation constructs in PrP-null background","pmids":["8635458"],"is_preprint":false},{"year":2000,"finding":"PrPC mediates signal transduction through a caveolin-1-dependent coupling to the tyrosine kinase Fyn upon antibody-mediated cross-linking; this signaling is restricted to fully differentiated serotonergic and noradrenergic neuronal cells and occurs primarily at neurites.","method":"Antibody cross-linking in neuronal differentiation cell model (1C11), Western blot for Fyn phosphorylation, caveolin-1 dependence assessed by overexpression/disruption","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — specific cell signaling readout, multiple cellular conditions tested, differentiation-dependent effect","pmids":["10988071"],"is_preprint":false},{"year":2002,"finding":"Crystal structure of the octapeptide HGGGW–Cu2+ complex reveals equatorial coordination of Cu2+ by the histidine imidazole, two deprotonated glycine amides, and a glycine carbonyl, with axial water bridging to the Trp indole; EPR and ESEEM confirm this structure is maintained in the full PrP octarepeat domain in solution and that the Gly-Cu linkage is unstable below pH ~6.5, suggesting a pH-dependent mechanism for Cu2+ release in endosomes.","method":"X-ray crystallography, S-band EPR, X-band ESEEM, HYSCORE spectroscopy on 15N-labeled peptides and full PrP octarepeat domain","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — atomic-resolution crystal structure complemented by multiple EPR methods on full domain","pmids":["11900542"],"is_preprint":false},{"year":2002,"finding":"Stress-inducible protein 1 (STI1) is a cell-surface ligand for PrPC; the interaction is high-affinity (Kd ~10-7 M), mapped to PrPC residues 113-128 and STI1 residues 230-245, confirmed by co-immunoprecipitation in vivo, and triggers neuroprotective signals that rescue cells from apoptosis.","method":"Cell-surface binding assays, GST pull-down, co-immunoprecipitation, peptide competition, neuroprotection assays (apoptosis rescue)","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — reciprocal binding, domain mapping, in vivo co-IP, functional neuroprotection readout","pmids":["12093732"],"is_preprint":false},{"year":2002,"finding":"Accumulation of cytosolic PrP (misfolded PrP retrotranslocated from the ER to the cytosol) is strongly neurotoxic in cultured cells and transgenic mice, producing fatal cerebellar ataxia with cerebellar degeneration and gliosis, establishing a mechanism for wild-type PrP to acquire neurotoxicity distinct from PrPSc.","method":"Transgenic mouse model expressing cytosolic PrP; immunofluorescence; histopathology (cerebellar degeneration, gliosis); cell toxicity assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — in vivo transgenic model with clear neurotoxic phenotype, replicated in cell culture","pmids":["12386337"],"is_preprint":false},{"year":1995,"finding":"PrPC is proteolytically cleaved in normal brain to generate a major C-terminal fragment (C1) with N-termini at His-111 or Met-112; C1 is glycosylated and GPI-anchored like PrPC, and this cleavage disrupts the neurotoxic/amyloidogenic region 106-126, suggesting C1 generation as a normal metabolic event that may limit pathogenicity.","method":"N-terminal sequencing of purified C1 fragment, Western blot, biochemical characterization (glycosylation, GPI-anchor, detergent solubility, protease resistance)","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — direct sequence identification of cleavage site, multiple orthogonal biochemical methods","pmids":["7642585"],"is_preprint":false},{"year":1986,"finding":"Molecular cloning of the human PrP cDNA revealed an open reading frame encoding a protein with an N-terminal signal peptide, two hydrophobic membrane-spanning segments, and two N-glycosylation sites; human PrP shares ~90% amino acid identity with hamster PrP.","method":"cDNA library screening, DNA sequencing, Northern blot analysis","journal":"DNA (Mary Ann Liebert, Inc.)","confidence":"High","confidence_rationale":"Tier 2 — foundational molecular cloning and sequence characterization of human PRNP","pmids":["3755672"],"is_preprint":false},{"year":2009,"finding":"Cellular PrPC is a high-affinity cell-surface receptor for soluble amyloid-beta oligomers (Aβo); Aβo binding to PrPC mediates blockade of hippocampal long-term potentiation, and PrP-null mice are resistant to Aβo-induced LTP inhibition; anti-PrP antibodies rescue synaptic plasticity.","method":"Expression cloning screen, surface plasmon resonance (Kd measurement), hippocampal slice electrophysiology (LTP), PrP knockout mice, anti-PrP antibody rescue","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — expression cloning identification, biophysical affinity measurement, in vivo genetic KO, antibody rescue — multiple orthogonal methods","pmids":["19242475"],"is_preprint":false},{"year":2012,"finding":"Aβ oligomers bound to postsynaptic PrPC activate Fyn kinase, leading to NR2B subunit phosphorylation of NMDARs, initial increase then loss of surface NMDARs, dendritic spine loss, and neuronal death; both PrPC and Fyn are required for Aβo-induced spine loss and Alzheimer transgene-driven seizures in mice.","method":"Co-immunoprecipitation, Fyn kinase assays, NMDAR surface expression by biotinylation, dendritic spine imaging, LDH cytotoxicity, PrP-null and Fyn-null mouse genetics, human AD brain extract assays","journal":"Nature Neuroscience","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal assays, reciprocal co-IP, genetic KO validation, human tissue","pmids":["22820466"],"is_preprint":false},{"year":2013,"finding":"Metabotropic glutamate receptor 5 (mGluR5) acts as a transmembrane co-receptor for the Aβo-PrPC complex at the postsynaptic density; PrPC and mGluR5 physically interact, mGluR5 couples PrPC-bound Aβo to intracellular Fyn and to elevated intracellular Ca2+, eEF2 phosphorylation, and dendritic spine loss; mGluR5 antagonism reverses learning/memory deficits and synapse loss in familial AD transgenic mice.","method":"Heterologous co-expression screen (Xenopus oocytes), co-immunoprecipitation (PrPC-mGluR5 interaction), Ca2+ imaging, Fyn kinase assays, dendritic spine counting, behavioral testing in AD transgenic mice, mGluR5 antagonist treatment","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 1-2 — reconstitution in oocytes + co-IP + in vivo pharmacological rescue, multiple orthogonal methods","pmids":["24012003"],"is_preprint":false},{"year":2003,"finding":"Monoclonal anti-PrP antibodies markedly reduce peripheral PrPSc levels and prion infectivity in a murine scrapie model when administered peripherally, and prolong survival >300 days beyond untreated controls, demonstrating that PrPC on the cell surface is a required substrate for prion propagation that can be blocked by antibody.","method":"In vivo murine scrapie model: passive antibody transfer, Western blot for PrPSc, bioassay for prion infectivity, survival analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — in vivo mechanistic intervention with infectivity bioassay and survival endpoint","pmids":["12621436"],"is_preprint":false},{"year":1995,"finding":"Synthetic PrP peptides encompassing the two alpha-helical domains of PrP, when in random-coil (not beta-sheet) conformation, form a complex with PrPC that induces many PrPSc-like properties: fibrous aggregation, sedimentation at 100,000×g, protease resistance, and high beta-sheet content; the pathogenic A117V mutation enhances complex formation, and anti-PrP antibody prevents it.","method":"In vitro mixing of synthetic peptides with PrPC, ultracentrifugation, circular dichroism, protease resistance assay, electron microscopy, antibody inhibition","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro conversion assay with multiple biophysical readouts and mutagenesis/antibody controls","pmids":["7479957"],"is_preprint":false},{"year":2003,"finding":"Cell-surface PrPC constitutively cycles between the plasma membrane and early endosomes via a clathrin-dependent mechanism; this pathway is consistent with a role for PrPC in cellular copper ion trafficking; mutations linked to inherited prion diseases display abnormalities in maturation and localization.","method":"Cell biological trafficking studies: internalization assays, endosome colocalization, clathrin-dependence experiments (review summarizing experimental findings)","journal":"British Medical Bulletin","confidence":"Medium","confidence_rationale":"Tier 2 — review synthesizing direct experimental localization/trafficking data, not primary paper","pmids":["14522850"],"is_preprint":false},{"year":2005,"finding":"PrPC cooperates with STI1 to upregulate SOD (superoxide dismutase) activity in neuronal cells; PrPC co-immunoprecipitates with STI1; inhibitory peptides against PrPC-STI1 binding (STI1 pep.1 and PrP(113-132)) reduce SOD activity and induce toxicity in PrPC-expressing but not in Prnp−/− cells; the octapeptide repeat region and N-terminal half of the hydrophobic region of PrPC are required for this effect.","method":"Co-immunoprecipitation (PrPC-STI1), inhibitory peptide treatments, SOD activity assay, apoptosis assay in Prnp−/− and wild-type neuronal cell lines","journal":"Biochemical and Biophysical Research Communications","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP plus functional SOD assay and domain-mapping in isogenic cell lines","pmids":["15670743"],"is_preprint":false},{"year":2004,"finding":"Anti-PrP monoclonal antibodies prevent PrPSc accumulation by retaining PrPC on the cell surface rather than allowing its internalization; mAbs binding the cell surface (regardless of epitope: C-terminal core or N-terminal octapeptide region) block PrPSc formation at ~1 nM EC50; forced internalization with dextran sulfate overcomes antibody protection.","method":"Flow cytometry (PrPC surface retention), prion-infected cell culture (PrPSc accumulation by Western blot), dextran sulfate internalization assay","journal":"The Journal of General Virology","confidence":"Medium","confidence_rationale":"Tier 2-3 — direct mechanistic cell biology with functional PrPSc readout, multiple antibody specificities tested","pmids":["15483265"],"is_preprint":false},{"year":2010,"finding":"The conserved middle region of PrP (positively charged segment + hydrophobic domain) is essential for lipid-induced PrP conversion: the hydrophobic domain mediates hydrophobic PrP-lipid interaction required for C-terminal protease resistance, while the positively charged region contributes to electrostatic lipid binding; disease-associated P102L/P105L mutations and the codon 129 polymorphism alter lipid-induced PrP conversion.","method":"In vitro proteinase K resistance assays of recombinant PrP mutants incubated with anionic lipids, lipid-binding assays, site-directed mutagenesis","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 — reconstituted in vitro conversion assay with systematic mutagenesis of multiple PrP domains","pmids":["20718504"],"is_preprint":false},{"year":2014,"finding":"PrPC undergoes α-cleavage near residue 109 by ADAM proteases (ADAM8, 10, 17) at three distinct sites; copper and zinc modulate proteolytic efficiency; the minimal lethal deletion segment in PrPC fully encompasses all three α-cleavage sites, suggesting that α-cleavage is essential for downregulating PrPC activity and that its blockade with retention of N-terminal residues 23-31 confers a toxic phenotype.","method":"In vitro ADAM protease cleavage assays with recombinant PrP, biophysical characterization of cleavage sites, analysis of published PrP deletion mutant phenotypes","journal":"Prion","confidence":"Medium","confidence_rationale":"Tier 2 — direct in vitro enzyme assay with metal modulation; lethality inference from published deletion mutant compilation","pmids":["24721836"],"is_preprint":false},{"year":2017,"finding":"GPI anchor-directed membrane association of PrPC is required for persistent PrPres propagation in cell culture; transmembrane PrPC variants (redirected away from lipid rafts) resist conversion by multiple prion strains and by both raft-associated and purified GPI-anchorless amyloid fibrils, implicating raft microdomains as the site of PrPC-to-PrPres conversion.","method":"PrP-knockout neuronal cell line (NpL2) transfected with GPI-anchored vs. transmembrane-anchored PrPC; infection with multiple prion strains; PrPres detection by Western blot","journal":"Journal of Virology","confidence":"High","confidence_rationale":"Tier 2 — genetic rescue in null background, multiple prion strains, two anchor types, isogenic comparison","pmids":["27847358"],"is_preprint":false},{"year":2013,"finding":"Autophagy delivers disease-associated misfolded PrP (T182A mutant) from the ER to lysosomes in a Golgi-independent manner; autophagy inhibition (ATG5 knockout or 3-MA) reduces PrP-lysosome colocalization and increases insoluble, protease-resistant PrP, while autophagy induction (rapamycin) reduces it, demonstrating autophagy functions as a quality-control mechanism limiting PrPSc accumulation.","method":"Time-lapse live-cell imaging (GFP-Mut-PrP + LysoTracker), ATG5−/− mouse embryonic fibroblasts, 3-MA and rapamycin treatments, protease resistance assays, LC3B colocalization","journal":"International Journal of Cell Biology","confidence":"Medium","confidence_rationale":"Tier 2 — live imaging + genetic KO + pharmacological modulation with functional PrPSc readout","pmids":["24454378"],"is_preprint":false},{"year":2013,"finding":"PrP peptide 106-126 (PrP106-126) induces temporal mitophagy in neuronal cells (N2a) that requires cardiolipin (CL) externalization to the mitochondrial surface; knockdown of CL synthase or CL translocation proteins (phospholipid scramblase-3, NDPK-D) reduces PrP106-126-induced mitophagy and decreases PINK1/DRP1 recruitment, while impairing CL redistribution leads to mitochondrial dysfunction.","method":"CL synthase/PLSCR3/NDPK-D siRNA knockdown, mitophagy assays, PINK1/Parkin/DRP1 recruitment by immunofluorescence, oxidative phosphorylation measurement, ROS detection in N2a cells","journal":"Frontiers in Molecular Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple siRNA knockdowns with mechanistic mitophagy readouts in neuronal cell model","pmids":["37333615"],"is_preprint":false},{"year":2024,"finding":"Creatine binds directly to PrP (identified by DARTS assay), inhibits PrP-mediated conversion of Fe3+ to Fe2+, and thereby decreases intracellular iron uptake, promoting ferroptosis resistance in ectopic endometrial stromal cells; creatine accumulation in endometriosis lesions thus exploits PrP's iron-regulatory activity to enhance cell survival.","method":"DARTS (drug affinity responsive target stabilization) assay, cellular iron assays, ferroptosis viability assays, creatine supplementation experiments in patient-derived cells","journal":"Advanced Science","confidence":"Medium","confidence_rationale":"Tier 2-3 — direct target identification by DARTS with functional iron/ferroptosis readout in disease-relevant cells","pmids":["39119937"],"is_preprint":false},{"year":2017,"finding":"The native α-helical state of PrP acts as an uncompetitive or noncompetitive inhibitor of PrP amyloid fibril formation in vitro; quantitative kinetic analysis shows that destabilization of the native state promotes amyloid formation by relieving this inhibition.","method":"Thioflavin T fluorescence kinetic assays, varying concentrations of pre-formed amyloid seeds, monomer, and denaturant; enzyme kinetic modeling","journal":"Scientific Reports","confidence":"Medium","confidence_rationale":"Tier 1 — quantitative in vitro kinetic reconstitution with multiple conditions and mechanistic modeling","pmids":["28373719"],"is_preprint":false},{"year":2017,"finding":"Semisynthetic PrP variants carrying PEG-based N-glycan mimics at glycosylation sites 181 and 197 do not form amyloid fibrils under conditions that cause wild-type PrP to aggregate; addition of as little as 10 mol% PEGylated PrP to wild-type PrP completely blocks aggregation, suggesting N-glycans sterically inhibit PrP aggregation in vivo.","method":"Semisynthetic protein chemistry, in vitro aggregation assays, CD spectroscopy, ThT fluorescence","journal":"Chemical Science","confidence":"Medium","confidence_rationale":"Tier 1 — reconstituted in vitro aggregation with synthetic glycan mimics and dose-response inhibition","pmids":["28989689"],"is_preprint":false},{"year":2020,"finding":"Goats homozygous for a naturally occurring nonsense mutation (Ter) in PRNP that blocks PrPC synthesis are completely resistant to scrapie after intracerebral inoculation (no clinical signs, no PrPSc, no vacuolation at 1260 days post-inoculation), while wild-type goats succumb at ~601 days; heterozygotes show delayed disease (~773 days), demonstrating that PrPC expression level is a prerequisite and rate-limiting factor for prion disease.","method":"Intracerebral prion inoculation of PRNP+/+, PRNP+/Ter, and PRNPTer/Ter goats; immunohistochemistry, enzyme immunoassay, RT-QuIC for PrPSc","journal":"Veterinary Research","confidence":"High","confidence_rationale":"Tier 2 — in vivo natural-mutation knockout in three genotypes with multiple PrPSc detection methods","pmids":["31924264"],"is_preprint":false},{"year":2013,"finding":"The ZIP5 zinc transporter ectodomain (a PrP-like domain from an LZT family member) co-localizes with PrPC at the cell surface and shares the same Rab5-positive endocytic vesicles, and adopts a dimeric α-helical fold similar to PrPC, supporting the evolutionary origin of the prion protein family from ancestral LZT zinc transporter genes.","method":"Confocal microscopy colocalization (ZIP5 and PrPC in neuroblastoma cells), Rab5 endocytic marker colocalization, recombinant expression and biophysical characterization (CD, SEC) of ZIP5 PrP-like domain","journal":"PLoS ONE","confidence":"Medium","confidence_rationale":"Tier 2-3 — direct localization and biophysical characterization, single study","pmids":["24039764"],"is_preprint":false}],"current_model":"PRNP encodes the cellular prion protein (PrPC), a GPI-anchored glycoprotein with a structured C-terminal domain (three α-helices, antiparallel β-sheet) and disordered N-terminal tail containing octapeptide Cu2+-binding repeats (coordinated via His-Gly-Gly equatorial/axial interactions); PrPC localizes to cholesterol-rich raft/caveolae-like membrane domains and cycles between the plasma membrane and endosomes via clathrin-dependent endocytosis, a process modulated by copper at low endosomal pH; at the cell surface, PrPC functions as a signal transduction protein (coupling via caveolin-1 to Fyn kinase) and as a high-affinity receptor for amyloid-β oligomers, which engage PrPC to activate Fyn, phosphorylate NR2B of NMDARs, and cause synaptic dysfunction through an mGluR5 co-receptor; PrPC also binds STI1 (residues 113-128) to trigger neuroprotective SOD activation and anti-apoptotic signals; normal PrPC metabolism involves α-cleavage near residue 109 by ADAM proteases releasing neuroprotective N1 and C1 fragments, and N-glycosylation at residues 181/197 sterically inhibits aggregation; pathogenic conversion to PrPSc requires GPI anchor-directed raft localization and is initiated via interaction of PrPC's first two α-helical domains with misfolded PrP templates, producing β-sheet-rich, protease-resistant, detergent-insoluble aggregates; the disease phenotype is modulated by codon 129 Met/Val and codon 178 polymorphisms, and by the extent of N-glycosylation; misfolded PrP escaping to the cytosol (retrotranslocated from the ER) is acutely neurotoxic independent of PrPSc, while autophagy and lysosomal degradation serve as quality-control pathways limiting PrPSc accumulation."},"narrative":{"teleology":[{"year":1986,"claim":"Cloning human PRNP cDNA established the primary structure of PrP—including signal peptide, N-glycosylation sites, and high conservation with hamster PrP—providing the molecular framework for all subsequent functional studies.","evidence":"cDNA library screening and DNA sequencing of human PrP","pmids":["3755672"],"confidence":"High","gaps":["No three-dimensional structure yet available","Function of glycosylation sites unknown","GPI anchoring not yet characterized"]},{"year":1989,"claim":"Identification of the P102L mutation in Gerstmann-Sträussler syndrome families established that single missense mutations in PRNP cause inherited prion disease, proving the gene is directly pathogenic and not merely a host factor.","evidence":"Genetic linkage analysis and DNA sequencing in two independent GSS pedigrees","pmids":["2564168"],"confidence":"High","gaps":["Mechanism by which P102L promotes misfolding unknown","Relationship between genetic and sporadic prion disease unclear"]},{"year":1991,"claim":"Two key discoveries—that codon 129 homozygosity predisposes to sporadic CJD and that octapeptide repeat expansions cause familial CJD—revealed that both coding polymorphisms and repeat-length variants govern prion disease susceptibility, implicating intermolecular PrP-PrP interactions in propagation.","evidence":"Case-control genotyping (codon 129) and PRNP sequencing with neuropathological/transmission validation (repeat expansions)","pmids":["1677164","1683708"],"confidence":"High","gaps":["Structural basis of codon 129 effect on conversion unknown","Minimum repeat expansion required for disease not defined"]},{"year":1992,"claim":"Linking the D178N mutation to both fatal familial insomnia and familial CJD—with the phenotype determined by cis codon 129 Met versus Val—demonstrated that a single mutation can produce distinct prion diseases through allele-specific conformational modulation of PrP.","evidence":"PRNP sequencing, proteinase K Western blot, and segregation analysis across 11 kindreds","pmids":["1439789","1346338"],"confidence":"High","gaps":["Structural difference between FFI-PrPSc and fCJD-PrPSc unknown","How codon 129 alters PrP folding trajectory not resolved"]},{"year":1995,"claim":"Identification of normal α-cleavage at His-111/Met-112 generating the C1 fragment, and reconstitution of PrPSc-like conversion in vitro using α-helical PrP peptides, together defined both the physiological processing that limits PrP toxicity and the minimal molecular interaction (α-helical domains) sufficient for pathogenic misfolding.","evidence":"N-terminal sequencing of purified C1 from brain; in vitro peptide-PrPC mixing with ultracentrifugation, CD, and protease resistance readouts","pmids":["7642585","7479957"],"confidence":"High","gaps":["Identity of the protease(s) performing α-cleavage in vivo not yet determined","Whether α-cleavage actively protects against prion propagation in vivo untested"]},{"year":1996,"claim":"Demonstrating that PrPC and PrPSc co-localize in caveolae-like raft domains—and that the N-terminal 49 residues are dispensable for scrapie susceptibility—established that raft microdomains are the conversion site and that PrP's C-terminal structured domain is sufficient for prion propagation.","evidence":"Detergent-resistant membrane fractionation in two species; transgenic PrP-null mouse rescue with N-terminally truncated PrP constructs","pmids":["8962161","8635458"],"confidence":"High","gaps":["Whether raft disruption prevents conversion in vivo not tested","Role of specific raft lipid species unknown"]},{"year":2000,"claim":"The NMR solution structure of full-length human PrP and the discovery of caveolin-1/Fyn kinase signaling transformed understanding of PrPC from a passive substrate for conversion to a structured signaling protein whose globular domain interacts with its disordered N-terminal tail.","evidence":"NMR spectroscopy of recombinant PrP(23-230); antibody cross-linking Fyn activation assay in differentiated 1C11 neuronal cells","pmids":["10618385","10988071"],"confidence":"High","gaps":["Endogenous PrPC ligands that trigger Fyn signaling unknown","Whether N-terminal tail modulates signaling not tested"]},{"year":2002,"claim":"Three advances—atomic-resolution Cu²⁺ coordination in octapeptide repeats, identification of STI1 as a neuroprotective PrPC ligand, and demonstration that cytosolic PrP is acutely neurotoxic—revealed PrPC as a copper-binding signaling receptor with a misfolding-independent neurotoxic pathway when mislocalized to the cytosol.","evidence":"X-ray crystallography and EPR of HGGGW-Cu²⁺; GST pull-down and co-IP of PrPC-STI1 with apoptosis rescue; transgenic mice expressing cytosolic PrP with cerebellar degeneration","pmids":["11900542","12093732","12386337"],"confidence":"High","gaps":["Whether Cu²⁺ binding is physiologically required for PrPC function in vivo unclear","Mechanism of cytosolic PrP toxicity at the molecular level unknown"]},{"year":2003,"claim":"Anti-PrP antibody therapy dramatically prolonged survival in scrapie-infected mice by blocking cell-surface PrPC availability, directly proving that surface PrPC is the rate-limiting substrate for prion propagation and validating immunotherapy as a therapeutic strategy.","evidence":"Passive anti-PrP monoclonal antibody transfer in murine scrapie model with survival, PrPSc, and infectivity bioassays","pmids":["12621436"],"confidence":"High","gaps":["CNS penetration of antibodies not achieved","Whether antibodies work post-clinical onset unknown"]},{"year":2009,"claim":"The discovery that PrPC is a high-affinity receptor for Aβ oligomers—mediating LTP blockade that is absent in PrP-null mice—unexpectedly connected PrPC to Alzheimer's disease synaptotoxicity, expanding its pathological relevance beyond prion diseases.","evidence":"Expression cloning screen, surface plasmon resonance, hippocampal slice electrophysiology in wild-type and PrP-KO mice, anti-PrP antibody rescue","pmids":["19242475"],"confidence":"High","gaps":["Binding site on PrPC for Aβo not precisely mapped","Whether PrPC-Aβo interaction occurs in human AD brain not directly shown"]},{"year":2012,"claim":"Elucidation of the downstream Aβo→PrPC→Fyn→NR2B phosphorylation cascade—causing NMDAR dysregulation, spine loss, and neuronal death—provided a complete signaling pathway linking PrPC to Alzheimer-type synaptic destruction.","evidence":"Co-IP, Fyn kinase assays, NMDAR surface biotinylation, spine imaging, PrP-null and Fyn-null mouse genetics","pmids":["22820466"],"confidence":"High","gaps":["Therapeutic efficacy of Fyn inhibition in AD models not tested in this study","Contribution of this pathway relative to PrPC-independent Aβo toxicity unclear"]},{"year":2013,"claim":"Identification of mGluR5 as the transmembrane co-receptor coupling extracellular PrPC-Aβo complexes to intracellular Fyn and Ca²⁺ signaling completed the receptor architecture and demonstrated pharmacological reversibility of cognitive deficits via mGluR5 antagonism.","evidence":"Reconstitution in Xenopus oocytes, co-IP of PrPC-mGluR5, Ca²⁺ imaging, behavioral rescue with mGluR5 antagonist in AD transgenic mice","pmids":["24012003"],"confidence":"High","gaps":["Structural basis of PrPC-mGluR5 interaction unknown","Whether mGluR5 antagonism is effective in human AD untested"]},{"year":2013,"claim":"Demonstrating that autophagy delivers misfolded PrP from the ER to lysosomes—and that autophagy inhibition increases protease-resistant PrP—identified autophagy as a cellular quality-control mechanism limiting PrPSc accumulation.","evidence":"Live-cell imaging of GFP-mutant PrP, ATG5-KO MEFs, 3-MA and rapamycin treatments with protease resistance readouts","pmids":["24454378"],"confidence":"Medium","gaps":["Whether autophagy induction clears PrPSc in vivo during active prion infection not tested","Receptor(s) mediating selective PrP autophagy not identified"]},{"year":2014,"claim":"Mapping three distinct ADAM protease α-cleavage sites near residue 109 and showing that the minimal lethal PrP deletion encompasses all three sites established α-cleavage as essential for limiting PrPC-intrinsic toxicity, with copper and zinc modulating cleavage efficiency.","evidence":"In vitro ADAM8/10/17 cleavage assays with recombinant PrP, metal modulation, correlation with published deletion mutant lethality data","pmids":["24721836"],"confidence":"Medium","gaps":["Which ADAM protease is rate-limiting for α-cleavage in neurons not determined","In vivo validation of copper/zinc modulation lacking"]},{"year":2017,"claim":"Three convergent findings—that GPI-anchored raft association is required for persistent PrPSc propagation, that the native α-helical state kinetically inhibits amyloid formation, and that N-glycans at positions 181/197 sterically block aggregation—defined the biophysical constraints governing the conversion threshold.","evidence":"GPI vs. transmembrane PrP in prion-infected null cells; ThT kinetic assays with enzyme-kinetic modeling; semisynthetic PEG-glycan PrP aggregation assays","pmids":["27847358","28373719","28989689"],"confidence":"High","gaps":["Whether glycosylation-site occupancy varies in disease-affected brain regions unknown","Kinetic model not validated with authentic brain-derived PrPSc seeds"]},{"year":2020,"claim":"Complete prion resistance in PRNP-null goats after intracerebral inoculation—with dose-dependent delay in heterozygotes—provided definitive in vivo proof that PrPC expression level is the rate-limiting determinant of prion disease.","evidence":"Intracerebral scrapie inoculation of naturally occurring PRNP-null, heterozygous, and wild-type goats with IHC, EIA, and RT-QuIC","pmids":["31924264"],"confidence":"High","gaps":["Whether PrPC ablation produces any long-term neurological deficits in goats not reported","Applicability to human PRNP reduction strategies not tested"]},{"year":2024,"claim":"The finding that creatine directly binds PrP and inhibits its Fe³⁺→Fe²⁺ reductase activity to confer ferroptosis resistance in endometriotic cells revealed an unanticipated iron-regulatory function for PrP outside the nervous system.","evidence":"DARTS target identification, cellular iron uptake assays, ferroptosis viability assays in patient-derived endometrial stromal cells","pmids":["39119937"],"confidence":"Medium","gaps":["Structural basis of creatine-PrP binding unknown","Whether PrP's iron reductase activity is relevant in neurons not established","Single study requiring independent replication"]},{"year":null,"claim":"Key unresolved questions include the high-resolution structure of infectious PrPSc, the identity of endogenous ligands that activate PrPC-Fyn signaling under physiological conditions, and whether therapeutic reduction of PrPC expression (e.g., ASO) can be tolerated long-term without compromising PrPC's neuroprotective and copper-trafficking functions.","evidence":"","pmids":[],"confidence":"Low","gaps":["No atomic-resolution PrPSc structure available","Physiological PrPC activating ligand unknown","Long-term safety of PrPC depletion in humans untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[8,14,15,16]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[10,20,28]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[22]},{"term_id":"GO:0140299","term_label":"molecular sensor activity","supporting_discovery_ids":[9,27]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6,8,13,17,21,24]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[19,31]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[11]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[25]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,14,15,16]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[14,15,16]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[25,26]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,2,3,4,5,18,24,30]}],"complexes":[],"partners":["FYN","CAV1","STIP1","GRM5","GRIN2B","ADAM10","ADAM17"],"other_free_text":[]},"mechanistic_narrative":"PRNP encodes the cellular prion protein (PrPC), a GPI-anchored glycoprotein whose structured C-terminal domain contains three α-helices and an antiparallel β-sheet, while its disordered N-terminal tail harbors octapeptide repeats that coordinate Cu²⁺ via His-Gly-Gly equatorial ligation [PMID:10618385, PMID:11900542]. PrPC resides in cholesterol-rich caveolae-like membrane rafts where it signals through caveolin-1–coupled Fyn kinase in differentiated neurons, serves as a high-affinity receptor for amyloid-β oligomers—activating Fyn/NR2B phosphorylation and mGluR5-dependent synaptic dysfunction—and engages STI1 to trigger neuroprotective SOD upregulation and anti-apoptotic signaling [PMID:10988071, PMID:19242475, PMID:22820466, PMID:24012003, PMID:12093732, PMID:15670743]. Pathogenic conversion to protease-resistant PrPSc requires GPI-anchor-directed raft localization and is modulated by codon 129 homozygosity, N-glycosylation at residues 181/197, and normal α-cleavage by ADAM proteases near residue 109 that disrupts the amyloidogenic region; misfolded PrP retrotranslocated to the cytosol is independently neurotoxic [PMID:27847358, PMID:1677164, PMID:29989689, PMID:24721836, PMID:12386337, PMID:8962161]. Missense mutations (P102L, D178N) and octapeptide repeat expansions in PRNP cause inherited prion diseases including Gerstmann-Sträussler syndrome, fatal familial insomnia, and familial CJD, with the codon 129 polymorphism on the mutant allele determining the clinical phenotype [PMID:2564168, PMID:1346338, PMID:1439789, PMID:1683708]."},"prefetch_data":{"uniprot":{"accession":"P04156","full_name":"Major prion protein","aliases":["ASCR","PrP27-30","PrP33-35C"],"length_aa":253,"mass_kda":27.7,"function":"Its primary physiological function is unclear. May play a role in neuronal development and synaptic plasticity. May be required for neuronal myelin sheath maintenance. May promote myelin homeostasis through acting as an agonist for ADGRG6 receptor. May play a role in iron uptake and iron homeostasis. Soluble oligomers are toxic to cultured neuroblastoma cells and induce apoptosis (in vitro) (By similarity). Association with GPC1 (via its heparan sulfate chains) targets PRNP to lipid rafts. Also provides Cu(2+) or Zn(2+) for the ascorbate-mediated GPC1 deaminase degradation of its heparan sulfate side chains (By similarity)","subcellular_location":"Cell membrane; Golgi apparatus","url":"https://www.uniprot.org/uniprotkb/P04156/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PRNP","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PRNP","total_profiled":1310},"omim":[{"mim_id":"613954","title":"FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 6; FTDALS6","url":"https://www.omim.org/entry/613954"},{"mim_id":"610653","title":"RIBOSOMAL RNA-PROCESSING 1; RRP1","url":"https://www.omim.org/entry/610653"},{"mim_id":"610447","title":"SHADOW OF PRION PROTEIN; SPRN","url":"https://www.omim.org/entry/610447"},{"mim_id":"610245","title":"SPINOCEREBELLAR ATAXIA 23; SCA23","url":"https://www.omim.org/entry/610245"},{"mim_id":"609917","title":"ERI1 EXORIBONUCLEASE FAMILY MEMBER 3; ERI3","url":"https://www.omim.org/entry/609917"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nuclear membrane","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"choroid plexus","ntpm":480.4}],"url":"https://www.proteinatlas.org/search/PRNP"},"hgnc":{"alias_symbol":["CD230","PRP","AltPrP"],"prev_symbol":["PRIP","GSS","CJD"]},"alphafold":{"accession":"P04156","domains":[{"cath_id":"1.10.790.10","chopping":"118-253","consensus_level":"medium","plddt":81.021,"start":118,"end":253}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P04156","model_url":"https://alphafold.ebi.ac.uk/files/AF-P04156-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P04156-F1-predicted_aligned_error_v6.png","plddt_mean":64.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRNP","jax_strain_url":"https://www.jax.org/strain/search?query=PRNP"},"sequence":{"accession":"P04156","fasta_url":"https://rest.uniprot.org/uniprotkb/P04156.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P04156/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P04156"}},"corpus_meta":[{"pmid":"8422996","id":"PMC_8422996","title":"Thiamine-repressible expression vectors pREP and pRIP for fission yeast.","date":"1993","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8422996","citation_count":970,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8635458","id":"PMC_8635458","title":"Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie.","date":"1996","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8635458","citation_count":746,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12386337","id":"PMC_12386337","title":"Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol.","date":"2002","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12386337","citation_count":383,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9343239","id":"PMC_9343239","title":"RNA aptamers specifically interact with the prion protein PrP.","date":"1997","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9343239","citation_count":175,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9263413","id":"PMC_9263413","title":"PrP genetics in sheep and the applications for scrapie and BSE.","date":"1997","source":"Trends in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/9263413","citation_count":163,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10903871","id":"PMC_10903871","title":"Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro.","date":"2000","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10903871","citation_count":131,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15962001","id":"PMC_15962001","title":"Immunodetection of disease-associated mutant PrP, which accelerates disease in GSS transgenic mice.","date":"2005","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15962001","citation_count":123,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14522850","id":"PMC_14522850","title":"Trafficking, turnover and membrane topology of PrP.","date":"2003","source":"British medical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/14522850","citation_count":116,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14522848","id":"PMC_14522848","title":"PrP knock-out and PrP transgenic mice in prion research.","date":"2003","source":"British medical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/14522848","citation_count":113,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30992411","id":"PMC_30992411","title":"Review of concentration yields in commercially available platelet-rich plasma (PRP) systems: a call for PRP standardization.","date":"2019","source":"Regional anesthesia and pain medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30992411","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7479957","id":"PMC_7479957","title":"Prion protein (PrP) synthetic peptides induce cellular PrP to acquire properties of the scrapie isoform.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7479957","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14522846","id":"PMC_14522846","title":"Biochemistry and structure of PrP(C) and PrP(Sc).","date":"2003","source":"British medical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/14522846","citation_count":99,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1679288","id":"PMC_1679288","title":"APP717, APP693, and PRIP gene mutations are rare in Alzheimer disease.","date":"1991","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1679288","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22043907","id":"PMC_22043907","title":"Upregulation of micro RNA-146a (miRNA-146a), a marker for inflammatory neurodegeneration, in sporadic Creutzfeldt-Jakob disease (sCJD) and Gerstmann-Straussler-Scheinker (GSS) syndrome.","date":"2011","source":"Journal of toxicology and environmental health. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/22043907","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23647538","id":"PMC_23647538","title":"The pH-triggered conversion of the PrP(c) to PrP(sc.).","date":"2013","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23647538","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28778873","id":"PMC_28778873","title":"Genetic PrP Prion Diseases.","date":"2018","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/28778873","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25489498","id":"PMC_25489498","title":"Platlet Rich Plasma (PRP) Improves Fat Grafting Outcomes.","date":"2013","source":"World journal of plastic surgery","url":"https://pubmed.ncbi.nlm.nih.gov/25489498","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22396643","id":"PMC_22396643","title":"PK-sensitive PrP is infectious and shares basic structural features with PK-resistant PrP.","date":"2012","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/22396643","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29414853","id":"PMC_29414853","title":"The Structure of PrPSc Prions.","date":"2018","source":"Pathogens (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/29414853","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15483265","id":"PMC_15483265","title":"Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation.","date":"2004","source":"The Journal of general virology","url":"https://pubmed.ncbi.nlm.nih.gov/15483265","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12467885","id":"PMC_12467885","title":"Molecules interacting with PRIP-2, a novel Ins(1,4,5)P3 binding protein type 2: Comparison with PRIP-1.","date":"2002","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/12467885","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26022925","id":"PMC_26022925","title":"The influence of PRNP polymorphisms on human prion disease susceptibility: an update.","date":"2015","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/26022925","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15148589","id":"PMC_15148589","title":"Polymorphisms of the prion protein gene (PRNP) in a Korean population.","date":"2004","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15148589","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12514748","id":"PMC_12514748","title":"Genomic characterization of the human prion protein (PrP) gene locus.","date":"2002","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/12514748","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18691383","id":"PMC_18691383","title":"Green tea extracts interfere with the stress-protective activity of PrP and the formation of PrP.","date":"2008","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18691383","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18258168","id":"PMC_18258168","title":"Progress and limits of PrP gene selection policy.","date":"2008","source":"Veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/18258168","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20718504","id":"PMC_20718504","title":"Role of the highly conserved middle region of prion protein (PrP) in PrP-lipid interaction.","date":"2010","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20718504","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14522849","id":"PMC_14522849","title":"Putative functions of PrP(C).","date":"2003","source":"British medical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/14522849","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15670743","id":"PMC_15670743","title":"PrP cooperates with STI1 to regulate SOD activity in PrP-deficient neuronal cell line.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15670743","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31042308","id":"PMC_31042308","title":"Platelet-Rich Plasma (PRP) From Older Males With Knee Osteoarthritis Depresses Chondrocyte Metabolism and Upregulates Inflammation.","date":"2019","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/31042308","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12814912","id":"PMC_12814912","title":"Channels formed with a mutant prion protein PrP(82-146) homologous to a 7-kDa fragment in diseased brain of GSS patients.","date":"2003","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12814912","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38114454","id":"PMC_38114454","title":"Gss deficiency causes age-related fertility impairment via ROS-triggered ferroptosis in the testes of mice.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38114454","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14745079","id":"PMC_14745079","title":"Polymorphisms within the prion (PrP) and prion-like protein (Doppel) genes in AD.","date":"2004","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/14745079","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15354865","id":"PMC_15354865","title":"The role of PrP in health and disease.","date":"2004","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15354865","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28934494","id":"PMC_28934494","title":"Derivatives of Bst-like Gss-polymerase with improved processivity and inhibitor tolerance.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/28934494","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31583788","id":"PMC_31583788","title":"Transition of the prion protein from a structured cellular form (PrPC ) to the infectious scrapie agent (PrPSc ).","date":"2019","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/31583788","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17426768","id":"PMC_17426768","title":"Genotype distribution of the prion protein gene (PRNP) promoter polymorphisms in Korean cattle.","date":"2006","source":"Genome","url":"https://pubmed.ncbi.nlm.nih.gov/17426768","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18217941","id":"PMC_18217941","title":"Genetic variability of the PRNP gene in goat breeds from Northern and Southern Italy.","date":"2008","source":"Journal of applied microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/18217941","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20339552","id":"PMC_20339552","title":"A camelid anti-PrP antibody abrogates PrP replication in prion-permissive neuroblastoma cell lines.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20339552","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31653880","id":"PMC_31653880","title":"Potential scrapie-associated polymorphisms of the prion protein gene (PRNP) in Korean native black goats.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31653880","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29523205","id":"PMC_29523205","title":"Pathologic and biochemical characterization of PrPSc from elk with PRNP polymorphisms at codon 132 after experimental infection with the chronic wasting disease agent.","date":"2018","source":"BMC veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/29523205","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24958194","id":"PMC_24958194","title":"Nonsense mutation in PRNP associated with clinical Alzheimer's disease.","date":"2014","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/24958194","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21728138","id":"PMC_21728138","title":"The PrP-like proteins Shadoo and Doppel.","date":"2011","source":"Topics in current chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21728138","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31852336","id":"PMC_31852336","title":"Chronic wasting disease associated with prion protein gene (PRNP) variation in Norwegian wild reindeer (Rangifer tarandus).","date":"2020","source":"Prion","url":"https://pubmed.ncbi.nlm.nih.gov/31852336","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24721836","id":"PMC_24721836","title":"PrP overdrive: does inhibition of α-cleavage contribute to PrP(C) toxicity and prion disease?","date":"2014","source":"Prion","url":"https://pubmed.ncbi.nlm.nih.gov/24721836","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26135918","id":"PMC_26135918","title":"Transmission Properties of Human PrP 102L Prions Challenge the Relevance of Mouse Models of GSS.","date":"2015","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/26135918","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1971924","id":"PMC_1971924","title":"A codon 129 polymorphism in the PRIP gene.","date":"1990","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/1971924","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19925901","id":"PMC_19925901","title":"Design and delivery of a cryptic PrP(C) epitope for induction of PrP(Sc)-specific antibody responses.","date":"2009","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/19925901","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24945349","id":"PMC_24945349","title":"Phospholipase C-related catalytically inactive protein (PRIP) regulates lipolysis in adipose tissue by modulating the phosphorylation of hormone-sensitive lipase.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24945349","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7535178","id":"PMC_7535178","title":"Preparation and characterization of antibodies against mouse prion protein (PrP) peptides.","date":"1995","source":"Clinical and diagnostic laboratory immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7535178","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9031631","id":"PMC_9031631","title":"Characterization of a prion protein (PrP) gene from rabbit; a species with apparent resistance to infection by prions.","date":"1997","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9031631","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7622046","id":"PMC_7622046","title":"A candidate marsupial PrP gene reveals two domains conserved in mammalian PrP proteins.","date":"1995","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/7622046","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34529657","id":"PMC_34529657","title":"Platelet HMGB1 in Platelet-Rich Plasma (PRP) promotes tendon wound healing.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34529657","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31924264","id":"PMC_31924264","title":"Goats naturally devoid of PrPC are resistant to scrapie.","date":"2020","source":"Veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/31924264","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17368456","id":"PMC_17368456","title":"Preliminary study on the receptor of gonad-stimulating substance (GSS) as a gonadotropin of starfish.","date":"2007","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17368456","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8594839","id":"PMC_8594839","title":"In situ hybridization and immunohistochemistry for prion protein (PrP) in bovine spongiform encephalopathy (BSE).","date":"1995","source":"Zentralblatt fur Veterinarmedizin. Reihe A","url":"https://pubmed.ncbi.nlm.nih.gov/8594839","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34620247","id":"PMC_34620247","title":"Review on PRNP genetics and susceptibility to chronic wasting disease of Cervidae.","date":"2021","source":"Veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/34620247","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32560489","id":"PMC_32560489","title":"Identification of Prion Disease-Related Somatic Mutations in the Prion Protein Gene (PRNP) in Cancer Patients.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32560489","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12415222","id":"PMC_12415222","title":"Do ambulatory-use Platelet-Rich Plasma (PRP) concentrates present risks?","date":"2002","source":"Medicina oral : organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal","url":"https://pubmed.ncbi.nlm.nih.gov/12415222","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23299511","id":"PMC_23299511","title":"Identification of miRNA encoded by Jatropha curcas from EST and GSS.","date":"2013","source":"Plant signaling & behavior","url":"https://pubmed.ncbi.nlm.nih.gov/23299511","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24039764","id":"PMC_24039764","title":"The ZIP5 ectodomain co-localizes with PrP and may acquire a PrP-like fold that assembles into a dimer.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24039764","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22437735","id":"PMC_22437735","title":"Unraveling the neuroprotective mechanisms of PrP (C) in excitotoxicity.","date":"2012","source":"Prion","url":"https://pubmed.ncbi.nlm.nih.gov/22437735","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12943661","id":"PMC_12943661","title":"Different isoforms of PRIP-interacting protein with methyltransferase domain/trimethylguanosine synthase localizes to the cytoplasm and nucleus.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12943661","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24812354","id":"PMC_24812354","title":"Phospholipase C-related catalytically inactive protein (PRIP) controls KIF5B-mediated insulin secretion.","date":"2014","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/24812354","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27847358","id":"PMC_27847358","title":"PrP Knockout Cells Expressing Transmembrane PrP Resist Prion Infection.","date":"2017","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/27847358","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17258625","id":"PMC_17258625","title":"Prion protein (PrP) in human teeth: an unprecedented pointer to PrP's function.","date":"2007","source":"Journal of endodontics","url":"https://pubmed.ncbi.nlm.nih.gov/17258625","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30896295","id":"PMC_30896295","title":"Autologous Platelet-Rich Plasma (CuteCell PRP) Safely Boosts In Vitro Human Fibroblast Expansion.","date":"2019","source":"Tissue engineering. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/30896295","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30480243","id":"PMC_30480243","title":"Prion Protein PRNP: A New Player in Innate Immunity? The Aβ Connection.","date":"2017","source":"Journal of Alzheimer's disease reports","url":"https://pubmed.ncbi.nlm.nih.gov/30480243","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22129783","id":"PMC_22129783","title":"FOXP2, APOE, and PRNP: new modulators in primary progressive aphasia.","date":"2012","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/22129783","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32516343","id":"PMC_32516343","title":"Spontaneous generation of prions and transmissible PrP amyloid in a humanised transgenic mouse model of A117V GSS.","date":"2020","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/32516343","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28989689","id":"PMC_28989689","title":"Semisynthetic prion protein (PrP) variants carrying glycan mimics at position 181 and 197 do not form fibrils.","date":"2017","source":"Chemical science","url":"https://pubmed.ncbi.nlm.nih.gov/28989689","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16622593","id":"PMC_16622593","title":"Prion protein gene (PRNP) polymorphisms in Xinjiang local sheep breeds in China.","date":"2006","source":"Archives of virology","url":"https://pubmed.ncbi.nlm.nih.gov/16622593","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14635114","id":"PMC_14635114","title":"Diagnostics in patients with glutathione synthetase deficiency but without mutations in the exons of the GSS gene.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/14635114","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22147650","id":"PMC_22147650","title":"Prion proteins (PRNP and PRND) are over-expressed in osteosarcoma.","date":"2011","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/22147650","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23911386","id":"PMC_23911386","title":"Phospholipase C-related but catalytically inactive protein, PRIP as a scaffolding protein for phospho-regulation.","date":"2013","source":"Advances in biological regulation","url":"https://pubmed.ncbi.nlm.nih.gov/23911386","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25364762","id":"PMC_25364762","title":"Regulation of PrP(C) signaling and processing by dimerization.","date":"2014","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/25364762","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20140032","id":"PMC_20140032","title":"Prion protein gene (PRNP) polymorphisms in native Chinese cattle.","date":"2010","source":"Genome","url":"https://pubmed.ncbi.nlm.nih.gov/20140032","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31410005","id":"PMC_31410005","title":"Early-onset Alzheimer's disease patient with prion (PRNP) p.Val180Ile mutation.","date":"2019","source":"Neuropsychiatric disease and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/31410005","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9681800","id":"PMC_9681800","title":"Molecular analysis of prion protein gene (PRNP) in Korean patients with Creutzfeldt-Jakob disease.","date":"1998","source":"Journal of Korean medical science","url":"https://pubmed.ncbi.nlm.nih.gov/9681800","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20028338","id":"PMC_20028338","title":"Creutzfeldt-Jakob disease with PRNP G114V mutation in a Chinese family.","date":"2009","source":"Acta neurologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/20028338","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41226837","id":"PMC_41226837","title":"Platelet-Rich Plasma (PRP): Molecular Mechanisms, Actions and Clinical Applications in Human Body.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41226837","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18068119","id":"PMC_18068119","title":"A monoclonal antibody (1D12) defines novel distribution patterns of prion protein (PrP) as granules in nucleus.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18068119","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31498962","id":"PMC_31498962","title":"Effects of PRP and LyPRP on osteogenic differentiation of MSCs.","date":"2019","source":"Journal of biomedical materials research. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/31498962","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26536866","id":"PMC_26536866","title":"Mammalian prion protein (PrP) forms conformationally different amyloid intracellular aggregates in bacteria.","date":"2015","source":"Microbial cell factories","url":"https://pubmed.ncbi.nlm.nih.gov/26536866","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17129366","id":"PMC_17129366","title":"Novel mutation of the PRNP gene of a clinical CJD case.","date":"2006","source":"BMC infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17129366","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22561193","id":"PMC_22561193","title":"Genotype patterns and characteristics of PRNP in the Korean population.","date":"2012","source":"Prion","url":"https://pubmed.ncbi.nlm.nih.gov/22561193","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30373672","id":"PMC_30373672","title":"Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [18F]Flortaucipir PET.","date":"2018","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/30373672","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35387866","id":"PMC_35387866","title":"Methionine homozygosity for PRNP polymorphism and susceptibility to human prion diseases.","date":"2022","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/35387866","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22634099","id":"PMC_22634099","title":"PRNP gene variation in Pakistani cattle and buffaloes.","date":"2012","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/22634099","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24454378","id":"PMC_24454378","title":"Early Delivery of Misfolded PrP from ER to Lysosomes by Autophagy.","date":"2013","source":"International journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/24454378","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39119937","id":"PMC_39119937","title":"Creatine Promotes Endometriosis by Inducing Ferroptosis Resistance via Suppression of PrP.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39119937","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28341745","id":"PMC_28341745","title":"Phospholipase C-related, but catalytically inactive protein (PRIP) up-regulates osteoclast differentiation via calcium-calcineurin-NFATc1 signaling.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28341745","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37333615","id":"PMC_37333615","title":"Cardiolipin externalization mediates prion protein (PrP) peptide 106-126-associated mitophagy and mitochondrial dysfunction.","date":"2023","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/37333615","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32098855","id":"PMC_32098855","title":"Autoantibodies against the prion protein in individuals with PRNP mutations.","date":"2020","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32098855","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17493775","id":"PMC_17493775","title":"Strategies for eliminating PrP(c) as substrate for prion conversion and for enhancing PrP(Sc) degradation.","date":"2007","source":"Veterinary microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/17493775","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17205391","id":"PMC_17205391","title":"Antibodies to a nonconjugated prion protein peptide 95-123 interfere with PrP( Sc ) propagation in prion-infected cells.","date":"2007","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/17205391","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26217959","id":"PMC_26217959","title":"Efficient PRNP deletion in bovine genome using gene-editing technologies in bovine cells.","date":"2015","source":"Prion","url":"https://pubmed.ncbi.nlm.nih.gov/26217959","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28373719","id":"PMC_28373719","title":"The native state of prion protein (PrP) directly inhibits formation of PrP-amyloid fibrils in vitro.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28373719","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26248157","id":"PMC_26248157","title":"Transgenic Rabbits Expressing Ovine PrP Are Susceptible to Scrapie.","date":"2015","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/26248157","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35988278","id":"PMC_35988278","title":"Protective Effects of Autologous ‎Platelet-Rich Plasma (PRP) on the Outcome of ‎Cryopreservation in Rabbit Sperm.","date":"2022","source":"Cellular and molecular biology (Noisy-le-Grand, France)","url":"https://pubmed.ncbi.nlm.nih.gov/35988278","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26871627","id":"PMC_26871627","title":"The Cellular Phase of Alzheimer's Disease.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26871627","citation_count":1446,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17192785","id":"PMC_17192785","title":"Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database.","date":"2007","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17192785","citation_count":1399,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19242475","id":"PMC_19242475","title":"Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.","date":"2009","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/19242475","citation_count":1272,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11283320","id":"PMC_11283320","title":"Prion diseases of humans and animals: their causes and molecular basis.","date":"2001","source":"Annual review of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/11283320","citation_count":1018,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10618385","id":"PMC_10618385","title":"NMR solution structure of the human prion protein.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10618385","citation_count":878,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24857020","id":"PMC_24857020","title":"Distinct tau prion strains propagate in cells and mice and define different tauopathies.","date":"2014","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/24857020","citation_count":790,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2564168","id":"PMC_2564168","title":"Linkage of a prion protein missense variant to Gerstmann-Sträussler syndrome.","date":"1989","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2564168","citation_count":728,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1677164","id":"PMC_1677164","title":"Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease.","date":"1991","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1677164","citation_count":713,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10988071","id":"PMC_10988071","title":"Signal transduction through prion protein.","date":"2000","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/10988071","citation_count":626,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16713569","id":"PMC_16713569","title":"A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16713569","citation_count":610,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1439789","id":"PMC_1439789","title":"Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism.","date":"1992","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/1439789","citation_count":568,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22820466","id":"PMC_22820466","title":"Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons.","date":"2012","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22820466","citation_count":543,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1346338","id":"PMC_1346338","title":"Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene.","date":"1992","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/1346338","citation_count":480,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24012003","id":"PMC_24012003","title":"Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein.","date":"2013","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/24012003","citation_count":480,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8962161","id":"PMC_8962161","title":"Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8962161","citation_count":451,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7642585","id":"PMC_7642585","title":"Truncated forms of the human prion protein in normal brain and in prion diseases.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7642585","citation_count":450,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12621436","id":"PMC_12621436","title":"Monoclonal antibodies inhibit prion replication and delay the development of prion disease.","date":"2003","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12621436","citation_count":383,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12093732","id":"PMC_12093732","title":"Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12093732","citation_count":336,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17500595","id":"PMC_17500595","title":"Huntingtin interacting proteins are genetic modifiers of neurodegeneration.","date":"2007","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17500595","citation_count":325,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16187142","id":"PMC_16187142","title":"Genetic prion disease: the EUROCJD experience.","date":"2005","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16187142","citation_count":322,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11900542","id":"PMC_11900542","title":"Molecular features of the copper binding sites in the octarepeat domain of the prion protein.","date":"2002","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11900542","citation_count":315,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3755672","id":"PMC_3755672","title":"Molecular cloning of a human prion protein cDNA.","date":"1986","source":"DNA (Mary Ann Liebert, Inc.)","url":"https://pubmed.ncbi.nlm.nih.gov/3755672","citation_count":311,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1683708","id":"PMC_1683708","title":"Transmissible familial Creutzfeldt-Jakob disease associated with five, seven, and eight extra octapeptide coding repeats in the PRNP gene.","date":"1991","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1683708","citation_count":297,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46770,"output_tokens":5230,"usd":0.10938},"stage2":{"model":"claude-opus-4-6","input_tokens":8741,"output_tokens":3985,"usd":0.214995},"total_usd":0.737564,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":59954,"output_tokens":8165,"usd":0.151169},"round2_rules_fired":"R2,R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":12221,"output_tokens":4543,"usd":0.26202}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"The amino-proximal segment of PrP(C) (first 49 N-terminal residues) is not required for conversion into the pathogenic PrP(Sc) isoform or for prion propagation, as demonstrated by transgenic mice expressing N-terminally truncated PrP that still developed fatal prion disease and accumulated PrP(Sc) after scrapie inoculation.\",\n      \"method\": \"Transgenic mouse model (PrP knockout mice rescued with truncated PrP transgenes), prion inoculation, PrP(Sc) accumulation assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean transgenic loss-of-function rescue with defined molecular and disease phenotype, replicated across multiple truncation constructs\",\n      \"pmids\": [\"8635458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Accumulation of even small amounts of cytosolic PrP (arising from retrotranslocation of misfolded PrP from the ER to the cytosol when proteasomal degradation is impaired) is strongly neurotoxic, causing cerebellar degeneration and gliosis in transgenic mice, establishing a mechanism for PrP neurotoxicity distinct from PrP(Sc).\",\n      \"method\": \"Transgenic mouse model expressing cytosolic PrP, cultured cell neurotoxicity assays, histopathology\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transgenic mouse model with defined neurodegeneration phenotype plus cell culture, replicated across two experimental systems\",\n      \"pmids\": [\"12386337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Synthetic PrP peptides spanning two alpha-helical domains of PrP, when mixed with PrP(C), induce it to form a complex with properties of PrP(Sc): fibrous aggregates, protease resistance, high beta-sheet content, and sedimentation at 100,000×g. The peptide must be in random coil (not beta-sheet) conformation for complex formation, and an anti-PrP antibody prevents the interaction.\",\n      \"method\": \"In vitro mixing assay, sedimentation, protease digestion, secondary structure analysis (CD), anti-PrP antibody blocking\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with multiple orthogonal biochemical readouts and mutagenesis/antibody controls\",\n      \"pmids\": [\"7479957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"RNA aptamers interact specifically with the N-terminal region (residues 23–52) of PrP(C); G-quartet structural motifs in the aptamers are essential for PrP recognition; the aptamers do not recognize PrP(Sc) in brain homogenates from scrapie-infected mice, revealing conformational specificity.\",\n      \"method\": \"SELEX aptamer selection, pulldown/supershift with anti-PrP antibodies, binding assays with mutant aptamers, G-quartet disruption mutagenesis\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding reconstitution with structure-activity relationship (G-quartet mutagenesis) and domain mapping\",\n      \"pmids\": [\"9343239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Cell surface PrP(C) constitutively cycles between the plasma membrane and early endosomes via a clathrin-dependent mechanism; this trafficking pathway is consistent with a role for PrP(C) in copper ion trafficking.\",\n      \"method\": \"Cell biological trafficking studies, clathrin pathway inhibition, subcellular fractionation\",\n      \"journal\": \"British medical bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — review summarizing experimental cell biology data from multiple studies; indirect citation of primary work\",\n      \"pmids\": [\"14522850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PrP(C) is anchored at the outer cell surface by a glycosylphosphatidylinositol (GPI) tail; it contains copper(2+)-binding octapeptide repeats in its flexible N-terminal half and a globular C-terminal domain with three alpha-helices, one short antiparallel beta-sheet, and a disulfide bond.\",\n      \"method\": \"Biochemical characterization, NMR structure of recombinant PrP\",\n      \"journal\": \"British medical bulletin\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure determination combined with biochemical domain analysis, widely replicated\",\n      \"pmids\": [\"14522848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Anti-PrP monoclonal antibodies that retain PrP(C) on the cell surface (blocking its normal internalization pathway) prevent PrP(Sc) accumulation in prion-infected cells, regardless of epitope specificity; internalization is required for PrP conversion, as dextran sulfate treatment enhanced internalization and antibody retention prevented it.\",\n      \"method\": \"Flow cytometry, antibody treatment of persistently prion-infected cells, PrP(Sc) accumulation assay, dextran sulfate rescue experiment\",\n      \"journal\": \"The Journal of general virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal pharmacological manipulation with defined molecular readout, multiple antibody epitopes tested\",\n      \"pmids\": [\"15483265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The highly conserved middle region of PrP (comprising a positively charged segment and a hydrophobic domain) is essential for lipid-induced conversion of PrP(C) to a proteinase K-resistant conformation; the hydrophobic domain deletion abolishes C-terminal PK resistance induced by anionic lipids, while disease-associated mutations P105L and P102L and the 129 polymorphism affect the strength of PrP-lipid interaction.\",\n      \"method\": \"In vitro binding assays with recombinant PrP mutants and anionic lipids, proteinase K resistance assays, site-directed mutagenesis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with domain-deletion and point mutants across multiple readouts\",\n      \"pmids\": [\"20718504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PrP(C) physically associates with stress-inducible protein 1 (STI1) via co-immunoprecipitation; this interaction, mediated by the octapeptide repeat region and N-terminal hydrophobic region of PrP(C), promotes superoxide dismutase (SOD) activity and cell survival; inhibitory peptides against PrP(C)-STI1 binding reduce SOD activity and are toxic in PrP-expressing but not Prnp-null cells.\",\n      \"method\": \"Immunoprecipitation, inhibitory peptide competition assay, SOD activity assay, cell viability assay in Prnp(-/-) vs wild-type neuronal cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP with functional validation by peptide inhibition, single lab study\",\n      \"pmids\": [\"15670743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Epigallocatechin gallate (EGCG) directly binds PrP(C) (demonstrated by isothermal titration calorimetry), destabilizing its native conformation and converting it to a detergent-insoluble, non-PrP(Sc) conformer that is rapidly internalized from the plasma membrane and degraded in lysosomes; EGCG also interferes with PrP(C)'s stress-protective function, sensitizing cells to stress; in scrapie-infected cells, EGCG treatment halted PrP(Sc) formation.\",\n      \"method\": \"Isothermal titration calorimetry, cell-based internalization and degradation assays, scrapie-infected cell PrP(Sc) assay, structure-activity relationship (gallate side chain variants)\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding measured by ITC with structure-activity validation, complemented by cell-based mechanistic assays\",\n      \"pmids\": [\"18691383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PrP fragment 82-146 (corresponding to the 7 kDa amyloid fragment in GSS brains) forms ion channels in lipid bilayers; the 106-126 region within this fragment is required for channel formation, and the channels are Cu2+-sensitive cation channels, implicating channel-forming activity as a mechanism of PrP-related neuronal membrane dysfunction.\",\n      \"method\": \"Lipid bilayer electrophysiology, scrambled peptide controls, Cu2+ and Cd2+ ion sensitivity assays\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct reconstitution in lipid bilayer with pharmacological and structural controls\",\n      \"pmids\": [\"12814912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PK-sensitive PrP(Sc) (sPrP(Sc)) and PK-resistant PrP(Sc) (rPrP(Sc)) fractions have comparable infectivity and share similar structural properties despite differing in multimer size distribution, PK sensitivity, and sedimentation; strain-dependent differences in sPrP(Sc)/rPrP(Sc) ratios were detected for two hamster strains (263K and Drowsy).\",\n      \"method\": \"Centrifugation fractionation, PK digestion, infectivity bioassay, protein misfolding cyclic amplification (PMCA)\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — infectivity bioassay combined with structural biochemical characterization; multiple complementary methods\",\n      \"pmids\": [\"22396643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GPI anchor-directed membrane localization of PrP(C) to raft microdomains is required for persistent PrP(Sc) propagation; transmembrane-anchored PrP(C) (redirected away from lipid rafts) does not support prion conversion even when seeded with exogenous PrPres from multiple strains in PrP knockout cells.\",\n      \"method\": \"PrP knockout neuronal cell line (NpL2) expressing GPI-anchored vs transmembrane PrP constructs, infection with multiple prion strains, PrP(Sc) propagation assays\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean knockout-rescue cell system with defined genetic manipulation, multiple prion strains and biochemical states tested\",\n      \"pmids\": [\"27847358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Misfolded PrP carrying the disease-associated T182A mutation is delivered from the ER to lysosomes via autophagy (Golgi-independent); autophagy inhibition (ATG5 knockout or 3-MA treatment) reduces Mut-PrP colocalization with lysosomes and increases protease-resistant PrP, while autophagy induction (rapamycin) reduces it, establishing autophagy as a quality control mechanism limiting misfolded PrP accumulation.\",\n      \"method\": \"Time-lapse live cell imaging, colocalization with LysoTracker and LC3B, ATG5(-/-) MEFs, pharmacological autophagy modulation (3-MA, rapamycin), PK resistance assay\",\n      \"journal\": \"International journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic (ATG5 KO) and pharmacological perturbation with multiple orthogonal imaging and biochemical readouts\",\n      \"pmids\": [\"24454378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PrP(C) undergoes alpha-cleavage near residue 109 by ADAM metalloproteinases (ADAM8, 10, and 17), each at 3 distinct cleavage sites; cleavage efficiency is modulated by copper and zinc; the lethal deletion phenotype in PrP(C) knockout-rescue mice maps precisely to the region encompassing all three alpha-cleavage sites, indicating alpha-cleavage is essential for downregulating PrP(C)'s intrinsic activity.\",\n      \"method\": \"In vitro ADAM enzyme cleavage assay, biophysical characterization, analysis of transgenic deletion mutant phenotypes\",\n      \"journal\": \"Prion\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro enzyme assay combined with genetic deletion analysis; partially mechanistic, review-type presentation\",\n      \"pmids\": [\"24721836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"N-glycans at positions 181 and 197 of PrP inhibit amyloid fibril formation; semisynthetic PrP variants carrying PEG glycan mimics at these sites do not form fibrils under conditions where wildtype PrP aggregates, and addition of as little as 10 mol% PEGylated PrP completely blocks wildtype PrP aggregation.\",\n      \"method\": \"Semisynthetic protein chemistry, in vitro aggregation assay (ThT fluorescence), CD spectroscopy\",\n      \"journal\": \"Chemical science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with site-specific chemical modification, quantitative aggregation kinetics\",\n      \"pmids\": [\"28989689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The native alpha-helical state of PrP acts as an inhibitor of its own amyloid fibril formation in vitro, functioning as an uncompetitive or noncompetitive inhibitor of amyloid formation as determined by kinetic analysis using enzyme kinetics models.\",\n      \"method\": \"In vitro amyloid formation assay (ThT fluorescence), kinetic modeling with varying concentrations of preformed amyloid, monomer, and denaturant\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative in vitro reconstitution with kinetic modeling across multiple conditions\",\n      \"pmids\": [\"28373719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PrP(C) co-localizes with ZIP5 (a LIV-1 subfamily zinc transporter) at the cell surface and in Rab5-positive endocytic vesicles of neuroblastoma cells; the PrP-like ectodomain of ZIP5 forms a dimeric, largely globular, alpha-helical fold similar to PrP(C), providing structural evidence for the evolutionary relationship between PrP and ZIP zinc transporters.\",\n      \"method\": \"Subcellular colocalization by fluorescence microscopy with Rab5 marker, mammalian cell expression and purification, biophysical characterization (CD spectroscopy, dimerization assay)\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct colocalization imaging with functional marker plus biophysical structural characterization; single lab\",\n      \"pmids\": [\"24039764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Goats homozygous for a natural nonsense mutation (Ter) in PRNP that abolishes PrP(C) synthesis are completely resistant to intracerebral scrapie prion inoculation (no PrP(Sc) detected, no clinical disease up to 1260 dpi), demonstrating that PrP(C) expression is an absolute prerequisite for prion propagation and disease.\",\n      \"method\": \"Intracerebral inoculation of naturally PrPC-null goats, immunohistochemistry, enzyme immunoassay, RT-QuIC\",\n      \"journal\": \"Veterinary research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — natural loss-of-function model with rigorous infectivity readouts, first demonstration in naturally null animals\",\n      \"pmids\": [\"31924264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PrP106-126 peptide induces cardiolipin externalization to the mitochondrial surface in N2a cells, which promotes PINK1/DRP1 recruitment and initiates mitophagy; knockdown of CL synthase or phospholipid scramblase-3/NDPK-D (enzymes controlling CL synthesis and translocation) significantly reduces PrP106-126-induced mitophagy and impairs oxidative phosphorylation, identifying CL externalization as a key mechanistic step in PrP-peptide-induced mitochondrial dysfunction.\",\n      \"method\": \"siRNA knockdown of CL synthesis/translocation enzymes, PINK1/Parkin/DRP1 recruitment assays, mitophagy quantification, oxidative phosphorylation measurement in N2a cells\",\n      \"journal\": \"Frontiers in molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown with multiple mechanistic readouts; single lab, cell line model\",\n      \"pmids\": [\"37333615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Creatine binds directly to PrP (identified by DARTS assay) at its active site, inhibits PrP-mediated conversion of Fe3+ to Fe2+, decreases cellular iron uptake, and thereby promotes ferroptosis resistance in ectopic endometrial stromal cells, contributing to endometriosis progression.\",\n      \"method\": \"Drug affinity-responsive target stabilization (DARTS) assay, iron uptake measurements, lipid peroxidation and ROS assays, cell viability under high-iron conditions\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding identified by DARTS with functional iron-regulatory readouts; single lab\",\n      \"pmids\": [\"39119937\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRNP encodes PrP(C), a GPI-anchored, copper-binding cell-surface glycoprotein whose N-terminal disordered domain interacts with ligands including STI1 (activating SOD), ADAM metalloproteinases (mediating protective alpha-cleavage near residue 109), and anionic lipids (via its conserved middle hydrophobic region); PrP(C) constitutively cycles between the plasma membrane and early endosomes via clathrin-dependent endocytosis, and its localization in GPI-enriched lipid raft microdomains is absolutely required for its template-directed conversion into the beta-sheet-rich, protease-resistant, infectious PrP(Sc) isoform; misfolded PrP is cleared via autophagy-mediated lysosomal delivery, while cytosolic accumulation of retrograde-transported PrP is independently neurotoxic; PrP(C) expression is obligatory for prion propagation, and its native alpha-helical fold suppresses spontaneous amyloid formation.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"NMR solution structure of human PrP(23-230) revealed a globular C-terminal domain (residues 125-228) containing three α-helices (144-154, 173-194, 200-228) and a short antiparallel β-sheet (128-131, 161-164), with an N-terminal flexibly disordered tail; local conformational states of helices 2 and 3 are influenced by N-terminal tail length.\",\n      \"method\": \"NMR spectroscopy (solution structure of recombinant full-length and truncated human PrP)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution NMR structure with multiple constructs, foundational paper\",\n      \"pmids\": [\"10618385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"A missense mutation at PRNP codon 102 (Pro→Leu) is linked to Gerstmann-Sträussler syndrome, establishing that a pathogenic mutation in the prion protein gene causes inherited prion disease.\",\n      \"method\": \"Genetic linkage analysis in GSS pedigrees; DNA sequencing of PRNP\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic linkage replicated across two independent pedigrees; foundational discovery\",\n      \"pmids\": [\"2564168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Homozygosity at PRNP codon 129 (Met/Met or Val/Val) strongly predisposes to sporadic Creutzfeldt-Jakob disease, indicating that heterozygosity at this polymorphic site is protective, consistent with a mechanism requiring intermolecular PrP-PrP interaction during prion propagation.\",\n      \"method\": \"Case-control genotyping of codon 129 in sporadic CJD patients versus normal controls\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — large case-control study, subsequently replicated worldwide; mechanistic inference supported by protein-only hypothesis\",\n      \"pmids\": [\"1677164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Fatal familial insomnia and a subtype of familial CJD are both linked to the same Asn178 mutation in PRNP, but the distinct disease phenotypes are determined by the codon 129 Met/Val polymorphism on the mutant allele: Met129-Asn178 segregates with FFI, Val129-Asn178 with familial CJD.\",\n      \"method\": \"Segregation analysis and PRNP sequencing/restriction analysis in multiple kindreds\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic allelic dissection across 11 kindreds (15 FFI + 15 fCJD affected members), foundational\",\n      \"pmids\": [\"1439789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Fatal familial insomnia is caused by a point mutation at PRNP codon 178 (Asp→Asn), producing a protease-resistant PrP isoform with a distinct fragment pattern from that of CJD, demonstrating that codon 178 mutation alters PrP conformation and disease phenotype.\",\n      \"method\": \"PRNP sequencing, proteinase K digestion + Western blot, restriction enzyme analysis, linkage analysis\",\n      \"journal\": \"The New England Journal of Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct mutation identification with biochemical characterization, LOD score 3.4\",\n      \"pmids\": [\"1346338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Insertions of 5, 7, or 8 extra octapeptide coding repeats in the PRNP gene (resulting in 10–13 total repeats) are associated with familial transmissible CJD, establishing that expansion of the octapeptide repeat region of PrP causes inherited prion disease.\",\n      \"method\": \"PRNP sequencing and family screening of confirmed neuropathologically and experimentally transmitted CJD cases\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutation-phenotype co-segregation with experimental transmission validation\",\n      \"pmids\": [\"1683708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Both PrPC and PrPSc co-localize in caveolae-like detergent-insoluble membrane domains (CLDs/rafts) isolated from scrapie-infected neuroblastoma cells and Syrian hamster brain, supporting the hypothesis that PrPSc formation occurs within these cholesterol-rich membrane microdomains.\",\n      \"method\": \"Subcellular fractionation (Triton X-100 and detergent-free sonication), sucrose gradient flotation, sulfo-NHS-biotin cell-surface labeling, Western blot\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two independent purification methods (detergent and detergent-free), confirmed in two species\",\n      \"pmids\": [\"8962161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"PrP transgenes lacking the N-terminal 26 or 49 amino-proximal residues fully restore susceptibility to scrapie, prion propagation, and PrPSc accumulation in PrP-knockout mice, demonstrating that the amino-proximal domain of PrPC is dispensable for conversion to PrPSc.\",\n      \"method\": \"Transgenic mouse inoculation with scrapie prions; Western blot for PrPSc accumulation; disease bioassay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic rescue experiment with multiple truncation constructs in PrP-null background\",\n      \"pmids\": [\"8635458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PrPC mediates signal transduction through a caveolin-1-dependent coupling to the tyrosine kinase Fyn upon antibody-mediated cross-linking; this signaling is restricted to fully differentiated serotonergic and noradrenergic neuronal cells and occurs primarily at neurites.\",\n      \"method\": \"Antibody cross-linking in neuronal differentiation cell model (1C11), Western blot for Fyn phosphorylation, caveolin-1 dependence assessed by overexpression/disruption\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — specific cell signaling readout, multiple cellular conditions tested, differentiation-dependent effect\",\n      \"pmids\": [\"10988071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Crystal structure of the octapeptide HGGGW–Cu2+ complex reveals equatorial coordination of Cu2+ by the histidine imidazole, two deprotonated glycine amides, and a glycine carbonyl, with axial water bridging to the Trp indole; EPR and ESEEM confirm this structure is maintained in the full PrP octarepeat domain in solution and that the Gly-Cu linkage is unstable below pH ~6.5, suggesting a pH-dependent mechanism for Cu2+ release in endosomes.\",\n      \"method\": \"X-ray crystallography, S-band EPR, X-band ESEEM, HYSCORE spectroscopy on 15N-labeled peptides and full PrP octarepeat domain\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — atomic-resolution crystal structure complemented by multiple EPR methods on full domain\",\n      \"pmids\": [\"11900542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Stress-inducible protein 1 (STI1) is a cell-surface ligand for PrPC; the interaction is high-affinity (Kd ~10-7 M), mapped to PrPC residues 113-128 and STI1 residues 230-245, confirmed by co-immunoprecipitation in vivo, and triggers neuroprotective signals that rescue cells from apoptosis.\",\n      \"method\": \"Cell-surface binding assays, GST pull-down, co-immunoprecipitation, peptide competition, neuroprotection assays (apoptosis rescue)\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding, domain mapping, in vivo co-IP, functional neuroprotection readout\",\n      \"pmids\": [\"12093732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Accumulation of cytosolic PrP (misfolded PrP retrotranslocated from the ER to the cytosol) is strongly neurotoxic in cultured cells and transgenic mice, producing fatal cerebellar ataxia with cerebellar degeneration and gliosis, establishing a mechanism for wild-type PrP to acquire neurotoxicity distinct from PrPSc.\",\n      \"method\": \"Transgenic mouse model expressing cytosolic PrP; immunofluorescence; histopathology (cerebellar degeneration, gliosis); cell toxicity assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic model with clear neurotoxic phenotype, replicated in cell culture\",\n      \"pmids\": [\"12386337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"PrPC is proteolytically cleaved in normal brain to generate a major C-terminal fragment (C1) with N-termini at His-111 or Met-112; C1 is glycosylated and GPI-anchored like PrPC, and this cleavage disrupts the neurotoxic/amyloidogenic region 106-126, suggesting C1 generation as a normal metabolic event that may limit pathogenicity.\",\n      \"method\": \"N-terminal sequencing of purified C1 fragment, Western blot, biochemical characterization (glycosylation, GPI-anchor, detergent solubility, protease resistance)\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct sequence identification of cleavage site, multiple orthogonal biochemical methods\",\n      \"pmids\": [\"7642585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"Molecular cloning of the human PrP cDNA revealed an open reading frame encoding a protein with an N-terminal signal peptide, two hydrophobic membrane-spanning segments, and two N-glycosylation sites; human PrP shares ~90% amino acid identity with hamster PrP.\",\n      \"method\": \"cDNA library screening, DNA sequencing, Northern blot analysis\",\n      \"journal\": \"DNA (Mary Ann Liebert, Inc.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — foundational molecular cloning and sequence characterization of human PRNP\",\n      \"pmids\": [\"3755672\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Cellular PrPC is a high-affinity cell-surface receptor for soluble amyloid-beta oligomers (Aβo); Aβo binding to PrPC mediates blockade of hippocampal long-term potentiation, and PrP-null mice are resistant to Aβo-induced LTP inhibition; anti-PrP antibodies rescue synaptic plasticity.\",\n      \"method\": \"Expression cloning screen, surface plasmon resonance (Kd measurement), hippocampal slice electrophysiology (LTP), PrP knockout mice, anti-PrP antibody rescue\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — expression cloning identification, biophysical affinity measurement, in vivo genetic KO, antibody rescue — multiple orthogonal methods\",\n      \"pmids\": [\"19242475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Aβ oligomers bound to postsynaptic PrPC activate Fyn kinase, leading to NR2B subunit phosphorylation of NMDARs, initial increase then loss of surface NMDARs, dendritic spine loss, and neuronal death; both PrPC and Fyn are required for Aβo-induced spine loss and Alzheimer transgene-driven seizures in mice.\",\n      \"method\": \"Co-immunoprecipitation, Fyn kinase assays, NMDAR surface expression by biotinylation, dendritic spine imaging, LDH cytotoxicity, PrP-null and Fyn-null mouse genetics, human AD brain extract assays\",\n      \"journal\": \"Nature Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal assays, reciprocal co-IP, genetic KO validation, human tissue\",\n      \"pmids\": [\"22820466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Metabotropic glutamate receptor 5 (mGluR5) acts as a transmembrane co-receptor for the Aβo-PrPC complex at the postsynaptic density; PrPC and mGluR5 physically interact, mGluR5 couples PrPC-bound Aβo to intracellular Fyn and to elevated intracellular Ca2+, eEF2 phosphorylation, and dendritic spine loss; mGluR5 antagonism reverses learning/memory deficits and synapse loss in familial AD transgenic mice.\",\n      \"method\": \"Heterologous co-expression screen (Xenopus oocytes), co-immunoprecipitation (PrPC-mGluR5 interaction), Ca2+ imaging, Fyn kinase assays, dendritic spine counting, behavioral testing in AD transgenic mice, mGluR5 antagonist treatment\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution in oocytes + co-IP + in vivo pharmacological rescue, multiple orthogonal methods\",\n      \"pmids\": [\"24012003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Monoclonal anti-PrP antibodies markedly reduce peripheral PrPSc levels and prion infectivity in a murine scrapie model when administered peripherally, and prolong survival >300 days beyond untreated controls, demonstrating that PrPC on the cell surface is a required substrate for prion propagation that can be blocked by antibody.\",\n      \"method\": \"In vivo murine scrapie model: passive antibody transfer, Western blot for PrPSc, bioassay for prion infectivity, survival analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo mechanistic intervention with infectivity bioassay and survival endpoint\",\n      \"pmids\": [\"12621436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Synthetic PrP peptides encompassing the two alpha-helical domains of PrP, when in random-coil (not beta-sheet) conformation, form a complex with PrPC that induces many PrPSc-like properties: fibrous aggregation, sedimentation at 100,000×g, protease resistance, and high beta-sheet content; the pathogenic A117V mutation enhances complex formation, and anti-PrP antibody prevents it.\",\n      \"method\": \"In vitro mixing of synthetic peptides with PrPC, ultracentrifugation, circular dichroism, protease resistance assay, electron microscopy, antibody inhibition\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro conversion assay with multiple biophysical readouts and mutagenesis/antibody controls\",\n      \"pmids\": [\"7479957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Cell-surface PrPC constitutively cycles between the plasma membrane and early endosomes via a clathrin-dependent mechanism; this pathway is consistent with a role for PrPC in cellular copper ion trafficking; mutations linked to inherited prion diseases display abnormalities in maturation and localization.\",\n      \"method\": \"Cell biological trafficking studies: internalization assays, endosome colocalization, clathrin-dependence experiments (review summarizing experimental findings)\",\n      \"journal\": \"British Medical Bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — review synthesizing direct experimental localization/trafficking data, not primary paper\",\n      \"pmids\": [\"14522850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PrPC cooperates with STI1 to upregulate SOD (superoxide dismutase) activity in neuronal cells; PrPC co-immunoprecipitates with STI1; inhibitory peptides against PrPC-STI1 binding (STI1 pep.1 and PrP(113-132)) reduce SOD activity and induce toxicity in PrPC-expressing but not in Prnp−/− cells; the octapeptide repeat region and N-terminal half of the hydrophobic region of PrPC are required for this effect.\",\n      \"method\": \"Co-immunoprecipitation (PrPC-STI1), inhibitory peptide treatments, SOD activity assay, apoptosis assay in Prnp−/− and wild-type neuronal cell lines\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP plus functional SOD assay and domain-mapping in isogenic cell lines\",\n      \"pmids\": [\"15670743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Anti-PrP monoclonal antibodies prevent PrPSc accumulation by retaining PrPC on the cell surface rather than allowing its internalization; mAbs binding the cell surface (regardless of epitope: C-terminal core or N-terminal octapeptide region) block PrPSc formation at ~1 nM EC50; forced internalization with dextran sulfate overcomes antibody protection.\",\n      \"method\": \"Flow cytometry (PrPC surface retention), prion-infected cell culture (PrPSc accumulation by Western blot), dextran sulfate internalization assay\",\n      \"journal\": \"The Journal of General Virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct mechanistic cell biology with functional PrPSc readout, multiple antibody specificities tested\",\n      \"pmids\": [\"15483265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The conserved middle region of PrP (positively charged segment + hydrophobic domain) is essential for lipid-induced PrP conversion: the hydrophobic domain mediates hydrophobic PrP-lipid interaction required for C-terminal protease resistance, while the positively charged region contributes to electrostatic lipid binding; disease-associated P102L/P105L mutations and the codon 129 polymorphism alter lipid-induced PrP conversion.\",\n      \"method\": \"In vitro proteinase K resistance assays of recombinant PrP mutants incubated with anionic lipids, lipid-binding assays, site-directed mutagenesis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstituted in vitro conversion assay with systematic mutagenesis of multiple PrP domains\",\n      \"pmids\": [\"20718504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PrPC undergoes α-cleavage near residue 109 by ADAM proteases (ADAM8, 10, 17) at three distinct sites; copper and zinc modulate proteolytic efficiency; the minimal lethal deletion segment in PrPC fully encompasses all three α-cleavage sites, suggesting that α-cleavage is essential for downregulating PrPC activity and that its blockade with retention of N-terminal residues 23-31 confers a toxic phenotype.\",\n      \"method\": \"In vitro ADAM protease cleavage assays with recombinant PrP, biophysical characterization of cleavage sites, analysis of published PrP deletion mutant phenotypes\",\n      \"journal\": \"Prion\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct in vitro enzyme assay with metal modulation; lethality inference from published deletion mutant compilation\",\n      \"pmids\": [\"24721836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GPI anchor-directed membrane association of PrPC is required for persistent PrPres propagation in cell culture; transmembrane PrPC variants (redirected away from lipid rafts) resist conversion by multiple prion strains and by both raft-associated and purified GPI-anchorless amyloid fibrils, implicating raft microdomains as the site of PrPC-to-PrPres conversion.\",\n      \"method\": \"PrP-knockout neuronal cell line (NpL2) transfected with GPI-anchored vs. transmembrane-anchored PrPC; infection with multiple prion strains; PrPres detection by Western blot\",\n      \"journal\": \"Journal of Virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic rescue in null background, multiple prion strains, two anchor types, isogenic comparison\",\n      \"pmids\": [\"27847358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Autophagy delivers disease-associated misfolded PrP (T182A mutant) from the ER to lysosomes in a Golgi-independent manner; autophagy inhibition (ATG5 knockout or 3-MA) reduces PrP-lysosome colocalization and increases insoluble, protease-resistant PrP, while autophagy induction (rapamycin) reduces it, demonstrating autophagy functions as a quality-control mechanism limiting PrPSc accumulation.\",\n      \"method\": \"Time-lapse live-cell imaging (GFP-Mut-PrP + LysoTracker), ATG5−/− mouse embryonic fibroblasts, 3-MA and rapamycin treatments, protease resistance assays, LC3B colocalization\",\n      \"journal\": \"International Journal of Cell Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — live imaging + genetic KO + pharmacological modulation with functional PrPSc readout\",\n      \"pmids\": [\"24454378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PrP peptide 106-126 (PrP106-126) induces temporal mitophagy in neuronal cells (N2a) that requires cardiolipin (CL) externalization to the mitochondrial surface; knockdown of CL synthase or CL translocation proteins (phospholipid scramblase-3, NDPK-D) reduces PrP106-126-induced mitophagy and decreases PINK1/DRP1 recruitment, while impairing CL redistribution leads to mitochondrial dysfunction.\",\n      \"method\": \"CL synthase/PLSCR3/NDPK-D siRNA knockdown, mitophagy assays, PINK1/Parkin/DRP1 recruitment by immunofluorescence, oxidative phosphorylation measurement, ROS detection in N2a cells\",\n      \"journal\": \"Frontiers in Molecular Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple siRNA knockdowns with mechanistic mitophagy readouts in neuronal cell model\",\n      \"pmids\": [\"37333615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Creatine binds directly to PrP (identified by DARTS assay), inhibits PrP-mediated conversion of Fe3+ to Fe2+, and thereby decreases intracellular iron uptake, promoting ferroptosis resistance in ectopic endometrial stromal cells; creatine accumulation in endometriosis lesions thus exploits PrP's iron-regulatory activity to enhance cell survival.\",\n      \"method\": \"DARTS (drug affinity responsive target stabilization) assay, cellular iron assays, ferroptosis viability assays, creatine supplementation experiments in patient-derived cells\",\n      \"journal\": \"Advanced Science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct target identification by DARTS with functional iron/ferroptosis readout in disease-relevant cells\",\n      \"pmids\": [\"39119937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The native α-helical state of PrP acts as an uncompetitive or noncompetitive inhibitor of PrP amyloid fibril formation in vitro; quantitative kinetic analysis shows that destabilization of the native state promotes amyloid formation by relieving this inhibition.\",\n      \"method\": \"Thioflavin T fluorescence kinetic assays, varying concentrations of pre-formed amyloid seeds, monomer, and denaturant; enzyme kinetic modeling\",\n      \"journal\": \"Scientific Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — quantitative in vitro kinetic reconstitution with multiple conditions and mechanistic modeling\",\n      \"pmids\": [\"28373719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Semisynthetic PrP variants carrying PEG-based N-glycan mimics at glycosylation sites 181 and 197 do not form amyloid fibrils under conditions that cause wild-type PrP to aggregate; addition of as little as 10 mol% PEGylated PrP to wild-type PrP completely blocks aggregation, suggesting N-glycans sterically inhibit PrP aggregation in vivo.\",\n      \"method\": \"Semisynthetic protein chemistry, in vitro aggregation assays, CD spectroscopy, ThT fluorescence\",\n      \"journal\": \"Chemical Science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro aggregation with synthetic glycan mimics and dose-response inhibition\",\n      \"pmids\": [\"28989689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Goats homozygous for a naturally occurring nonsense mutation (Ter) in PRNP that blocks PrPC synthesis are completely resistant to scrapie after intracerebral inoculation (no clinical signs, no PrPSc, no vacuolation at 1260 days post-inoculation), while wild-type goats succumb at ~601 days; heterozygotes show delayed disease (~773 days), demonstrating that PrPC expression level is a prerequisite and rate-limiting factor for prion disease.\",\n      \"method\": \"Intracerebral prion inoculation of PRNP+/+, PRNP+/Ter, and PRNPTer/Ter goats; immunohistochemistry, enzyme immunoassay, RT-QuIC for PrPSc\",\n      \"journal\": \"Veterinary Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo natural-mutation knockout in three genotypes with multiple PrPSc detection methods\",\n      \"pmids\": [\"31924264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The ZIP5 zinc transporter ectodomain (a PrP-like domain from an LZT family member) co-localizes with PrPC at the cell surface and shares the same Rab5-positive endocytic vesicles, and adopts a dimeric α-helical fold similar to PrPC, supporting the evolutionary origin of the prion protein family from ancestral LZT zinc transporter genes.\",\n      \"method\": \"Confocal microscopy colocalization (ZIP5 and PrPC in neuroblastoma cells), Rab5 endocytic marker colocalization, recombinant expression and biophysical characterization (CD, SEC) of ZIP5 PrP-like domain\",\n      \"journal\": \"PLoS ONE\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct localization and biophysical characterization, single study\",\n      \"pmids\": [\"24039764\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRNP encodes the cellular prion protein (PrPC), a GPI-anchored glycoprotein with a structured C-terminal domain (three α-helices, antiparallel β-sheet) and disordered N-terminal tail containing octapeptide Cu2+-binding repeats (coordinated via His-Gly-Gly equatorial/axial interactions); PrPC localizes to cholesterol-rich raft/caveolae-like membrane domains and cycles between the plasma membrane and endosomes via clathrin-dependent endocytosis, a process modulated by copper at low endosomal pH; at the cell surface, PrPC functions as a signal transduction protein (coupling via caveolin-1 to Fyn kinase) and as a high-affinity receptor for amyloid-β oligomers, which engage PrPC to activate Fyn, phosphorylate NR2B of NMDARs, and cause synaptic dysfunction through an mGluR5 co-receptor; PrPC also binds STI1 (residues 113-128) to trigger neuroprotective SOD activation and anti-apoptotic signals; normal PrPC metabolism involves α-cleavage near residue 109 by ADAM proteases releasing neuroprotective N1 and C1 fragments, and N-glycosylation at residues 181/197 sterically inhibits aggregation; pathogenic conversion to PrPSc requires GPI anchor-directed raft localization and is initiated via interaction of PrPC's first two α-helical domains with misfolded PrP templates, producing β-sheet-rich, protease-resistant, detergent-insoluble aggregates; the disease phenotype is modulated by codon 129 Met/Val and codon 178 polymorphisms, and by the extent of N-glycosylation; misfolded PrP escaping to the cytosol (retrotranslocated from the ER) is acutely neurotoxic independent of PrPSc, while autophagy and lysosomal degradation serve as quality-control pathways limiting PrPSc accumulation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PRNP encodes PrP(C), a GPI-anchored, copper- and zinc-binding cell-surface glycoprotein whose native alpha-helical fold actively suppresses its own amyloid fibril formation, with N-glycans at positions 181 and 197 providing additional protection against aggregation [PMID:28373719, PMID:28989689]. PrP(C) constitutively cycles between the plasma membrane and early endosomes via clathrin-dependent endocytosis, and its GPI-directed localization to lipid raft microdomains is absolutely required for template-directed conversion into the protease-resistant, infectious PrP(Sc) isoform—a process that also requires internalization from the cell surface [PMID:27847358, PMID:15483265]. PrP(C) expression is obligatory for prion propagation and disease, as naturally PrP-null goats are completely resistant to scrapie inoculation [PMID:31924264]; independently of PrP(Sc) formation, cytosolic accumulation of retrotranslocated PrP causes neurodegeneration, while autophagy-mediated lysosomal delivery clears misfolded PrP as a quality control mechanism [PMID:12386337, PMID:24454378]. PrP(C) interacts with STI1 to promote superoxide dismutase activity and cell survival, undergoes protective alpha-cleavage by ADAM8/10/17 near residue 109, and participates in iron redox chemistry that modulates cellular iron uptake [PMID:15670743, PMID:24721836, PMID:39119937].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing that PrP(C) can be directly converted to a PrP(Sc)-like state by peptide-mediated template interaction resolved the central question of how a normal protein could adopt an infectious conformation.\",\n      \"evidence\": \"In vitro mixing of synthetic PrP peptides with PrP(C) producing protease-resistant, beta-sheet-rich aggregates, blocked by anti-PrP antibody\",\n      \"pmids\": [\"7479957\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No cellular context for conversion\", \"Stoichiometry and kinetics of conversion not defined\", \"Relationship between in vitro aggregates and in vivo infectivity unclear\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Determining that the N-terminal 49 residues are dispensable for PrP(Sc) conversion and prion disease narrowed the conversion-competent domain to the structured C-terminal region and intervening middle domain.\",\n      \"evidence\": \"Transgenic mice expressing N-terminally truncated PrP developed fatal scrapie and accumulated PrP(Sc) after inoculation\",\n      \"pmids\": [\"8635458\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Minimal conversion-competent fragment not defined\", \"Role of octapeptide repeats in disease kinetics not resolved\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identifying that RNA aptamers bind PrP(C) specifically at the N-terminal region (residues 23–52) via G-quartet motifs, but not PrP(Sc), demonstrated that the N-terminus is conformationally accessible in PrP(C) and structurally distinct in PrP(Sc).\",\n      \"evidence\": \"SELEX selection, binding assays with G-quartet mutagenesis and domain mapping\",\n      \"pmids\": [\"9343239\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biological role of nucleic acid–PrP interactions unknown\", \"Whether aptamer binding modulates conversion not tested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrating that cytosolic PrP accumulation is neurotoxic independent of PrP(Sc) established a distinct, proteasome-linked mechanism of PrP-mediated neurodegeneration.\",\n      \"evidence\": \"Transgenic mice expressing cytosolic PrP developed cerebellar degeneration; corroborated in cultured cells\",\n      \"pmids\": [\"12386337\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular targets of cytosolic PrP toxicity unidentified\", \"Whether cytosolic PrP contributes to sporadic prion disease unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Characterizing PrP fragment 82–146 as forming copper-sensitive cation channels in lipid bilayers provided a biophysical mechanism for how PrP fragments could directly compromise neuronal membrane integrity.\",\n      \"evidence\": \"Reconstituted lipid bilayer electrophysiology with scrambled peptide controls and ion sensitivity assays\",\n      \"pmids\": [\"12814912\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Channel formation not demonstrated in intact cells\", \"Relevance to in vivo neurotoxicity not established\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Establishing that PrP(C) cycles between plasma membrane and early endosomes via clathrin-dependent endocytosis, combined with its GPI-anchored, copper-binding structural architecture, defined the normal trafficking itinerary of the protein.\",\n      \"evidence\": \"Cell biological trafficking studies with clathrin pathway inhibition; NMR structure of recombinant PrP\",\n      \"pmids\": [\"14522850\", \"14522848\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signal initiating endocytosis of a GPI-anchored protein not identified\", \"Whether copper binding triggers internalization not resolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showing that antibody-mediated retention of PrP(C) on the cell surface blocks PrP(Sc) accumulation demonstrated that internalization is required for prion conversion, placing the conversion event in an endocytic compartment.\",\n      \"evidence\": \"Flow cytometry and PrP(Sc) accumulation assays in prion-infected cells treated with anti-PrP antibodies of multiple epitopes\",\n      \"pmids\": [\"15483265\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise endocytic compartment of conversion not identified\", \"Whether conversion occurs during recycling or in late endosomes/lysosomes unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identifying STI1 as a direct interaction partner of PrP(C) that activates SOD activity and promotes cell survival linked PrP(C) to oxidative stress protection as a physiological function.\",\n      \"evidence\": \"Co-immunoprecipitation, inhibitory peptide competition, SOD activity and cell viability assays in Prnp-null vs wild-type neurons\",\n      \"pmids\": [\"15670743\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Awaits independent replication by additional groups\", \"In vivo significance of PrP–STI1 interaction not demonstrated\", \"Mechanism by which PrP–STI1 activates SOD not defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrating that EGCG directly binds PrP(C), destabilizes it into a non-PrP(Sc) conformer that is rapidly internalized and degraded in lysosomes, showed that pharmacological manipulation of PrP(C) folding can redirect it to degradation and block PrP(Sc) formation.\",\n      \"evidence\": \"ITC binding measurement, cell-based internalization/degradation assays, PrP(Sc) inhibition in scrapie-infected cells with structure-activity controls\",\n      \"pmids\": [\"18691383\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy not demonstrated\", \"Whether lysosomal degradation of destabilized PrP proceeds via autophagy not determined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defining the conserved middle hydrophobic domain as essential for lipid-induced conversion to protease-resistant PrP, with disease mutations P102L/P105L modulating lipid interaction strength, established a mechanistic link between membrane lipid composition and PrP misfolding.\",\n      \"evidence\": \"In vitro binding assays with domain-deletion and point mutants, PK resistance assays with anionic lipids\",\n      \"pmids\": [\"20718504\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo lipid species driving conversion not identified\", \"Structural basis of lipid-induced conformational change not resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Establishing that PK-sensitive PrP(Sc) carries infectivity comparable to PK-resistant PrP(Sc) overturned the assumption that protease resistance defines the infectious unit and broadened the definition of pathogenic PrP conformers.\",\n      \"evidence\": \"Centrifugation fractionation, PK digestion, infectivity bioassay, and PMCA with two hamster prion strains\",\n      \"pmids\": [\"22396643\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural difference between sPrP(Sc) and rPrP(Sc) at atomic level unknown\", \"Whether sPrP(Sc) is a precursor to rPrP(Sc) or an independent species not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrating that misfolded PrP is delivered from the ER to lysosomes via autophagy (bypassing Golgi), and that autophagy inhibition increases protease-resistant PrP, identified autophagy as a critical quality control pathway limiting PrP misfolding.\",\n      \"evidence\": \"Live cell imaging, LC3B/LysoTracker colocalization, ATG5-knockout MEFs, pharmacological autophagy modulation\",\n      \"pmids\": [\"24454378\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether autophagy clears PrP(Sc) as efficiently as misfolded mutant PrP not tested\", \"Selective autophagy receptor for PrP not identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapping alpha-cleavage of PrP(C) by ADAM8/10/17 to three sites near residue 109 and linking the cleavage region to the lethal deletion phenotype in transgenic mice established alpha-cleavage as a protective processing step that downregulates PrP(C)'s intrinsic neurotoxic potential.\",\n      \"evidence\": \"In vitro ADAM enzyme cleavage assay, biophysical characterization, correlation with transgenic deletion mutant phenotypes\",\n      \"pmids\": [\"24721836\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo loss of specific ADAM protease not tested for PrP cleavage phenotype\", \"Functional consequence of individual cleavage sites not resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrating that GPI-anchored PrP(C) in lipid rafts—but not transmembrane-anchored PrP outside rafts—supports prion conversion established that lipid raft localization is an absolute requirement for PrP(Sc) propagation.\",\n      \"evidence\": \"PrP knockout neuronal cells expressing GPI- vs transmembrane-anchored PrP, infection with multiple prion strains\",\n      \"pmids\": [\"27847358\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which raft-resident cofactors or lipid species are required not identified\", \"Whether raft requirement reflects proximity to a co-factor or membrane environment\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showing that native alpha-helical PrP(C) acts as a kinetic inhibitor of its own amyloid formation, and that N-glycans at positions 181/197 independently block fibrillization, revealed two built-in protective mechanisms against spontaneous prion conversion.\",\n      \"evidence\": \"In vitro ThT amyloid kinetics with varying monomer/fibril concentrations; semisynthetic PEG-glycan PrP variants with quantitative aggregation assays\",\n      \"pmids\": [\"28373719\", \"28989689\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether glycan protection operates in vivo not demonstrated\", \"Structural mechanism by which glycans block fibril elongation unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrating complete scrapie resistance in naturally PrP-null goats provided definitive in vivo proof that PrP(C) expression is an absolute prerequisite for prion propagation and clinical disease.\",\n      \"evidence\": \"Intracerebral scrapie inoculation of PRNP-null goats, followed up to 1260 dpi with IHC, EIA, and RT-QuIC\",\n      \"pmids\": [\"31924264\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PrP-null animals show subtle neurological phenotypes under other stresses unknown\", \"Compensatory mechanisms in PrP-null animals not explored\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identifying PrP as a mediator of Fe3+-to-Fe2+ conversion and cellular iron uptake linked PrP(C) to ferroptosis regulation and provided a non-prion disease context (endometriosis) for PrP function.\",\n      \"evidence\": \"DARTS assay for creatine–PrP binding, iron uptake and lipid peroxidation measurements in endometrial stromal cells\",\n      \"pmids\": [\"39119937\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Iron reductase activity of PrP not reconstituted with purified protein\", \"Relevance of PrP-mediated iron uptake to neuronal physiology not established\", \"Single lab study awaiting independent replication\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The precise three-dimensional structure of infectious PrP(Sc) and the atomic-level mechanism of template-directed conversion remain unresolved, as does the identity of the selective autophagy receptor for PrP and the endogenous physiological ligand or function that explains PrP(C)'s evolutionary conservation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of authentic PrP(Sc)\", \"Endogenous physiological function of PrP(C) not definitively established\", \"Selective autophagy receptor for misfolded PrP unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [7, 10]},\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [20]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [4, 5, 6, 12, 17]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [4, 17]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1, 13]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [9, 13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 2, 7, 11, 12, 18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"STI1\",\n      \"ADAM8\",\n      \"ADAM10\",\n      \"ADAM17\",\n      \"ZIP5\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"PRNP encodes the cellular prion protein (PrPC), a GPI-anchored glycoprotein whose structured C-terminal domain contains three α-helices and an antiparallel β-sheet, while its disordered N-terminal tail harbors octapeptide repeats that coordinate Cu²⁺ via His-Gly-Gly equatorial ligation [PMID:10618385, PMID:11900542]. PrPC resides in cholesterol-rich caveolae-like membrane rafts where it signals through caveolin-1–coupled Fyn kinase in differentiated neurons, serves as a high-affinity receptor for amyloid-β oligomers—activating Fyn/NR2B phosphorylation and mGluR5-dependent synaptic dysfunction—and engages STI1 to trigger neuroprotective SOD upregulation and anti-apoptotic signaling [PMID:10988071, PMID:19242475, PMID:22820466, PMID:24012003, PMID:12093732, PMID:15670743]. Pathogenic conversion to protease-resistant PrPSc requires GPI-anchor-directed raft localization and is modulated by codon 129 homozygosity, N-glycosylation at residues 181/197, and normal α-cleavage by ADAM proteases near residue 109 that disrupts the amyloidogenic region; misfolded PrP retrotranslocated to the cytosol is independently neurotoxic [PMID:27847358, PMID:1677164, PMID:29989689, PMID:24721836, PMID:12386337, PMID:8962161]. Missense mutations (P102L, D178N) and octapeptide repeat expansions in PRNP cause inherited prion diseases including Gerstmann-Sträussler syndrome, fatal familial insomnia, and familial CJD, with the codon 129 polymorphism on the mutant allele determining the clinical phenotype [PMID:2564168, PMID:1346338, PMID:1439789, PMID:1683708].\",\n  \"teleology\": [\n    {\n      \"year\": 1986,\n      \"claim\": \"Cloning human PRNP cDNA established the primary structure of PrP—including signal peptide, N-glycosylation sites, and high conservation with hamster PrP—providing the molecular framework for all subsequent functional studies.\",\n      \"evidence\": \"cDNA library screening and DNA sequencing of human PrP\",\n      \"pmids\": [\"3755672\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No three-dimensional structure yet available\", \"Function of glycosylation sites unknown\", \"GPI anchoring not yet characterized\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Identification of the P102L mutation in Gerstmann-Sträussler syndrome families established that single missense mutations in PRNP cause inherited prion disease, proving the gene is directly pathogenic and not merely a host factor.\",\n      \"evidence\": \"Genetic linkage analysis and DNA sequencing in two independent GSS pedigrees\",\n      \"pmids\": [\"2564168\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which P102L promotes misfolding unknown\", \"Relationship between genetic and sporadic prion disease unclear\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Two key discoveries—that codon 129 homozygosity predisposes to sporadic CJD and that octapeptide repeat expansions cause familial CJD—revealed that both coding polymorphisms and repeat-length variants govern prion disease susceptibility, implicating intermolecular PrP-PrP interactions in propagation.\",\n      \"evidence\": \"Case-control genotyping (codon 129) and PRNP sequencing with neuropathological/transmission validation (repeat expansions)\",\n      \"pmids\": [\"1677164\", \"1683708\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of codon 129 effect on conversion unknown\", \"Minimum repeat expansion required for disease not defined\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Linking the D178N mutation to both fatal familial insomnia and familial CJD—with the phenotype determined by cis codon 129 Met versus Val—demonstrated that a single mutation can produce distinct prion diseases through allele-specific conformational modulation of PrP.\",\n      \"evidence\": \"PRNP sequencing, proteinase K Western blot, and segregation analysis across 11 kindreds\",\n      \"pmids\": [\"1439789\", \"1346338\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural difference between FFI-PrPSc and fCJD-PrPSc unknown\", \"How codon 129 alters PrP folding trajectory not resolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identification of normal α-cleavage at His-111/Met-112 generating the C1 fragment, and reconstitution of PrPSc-like conversion in vitro using α-helical PrP peptides, together defined both the physiological processing that limits PrP toxicity and the minimal molecular interaction (α-helical domains) sufficient for pathogenic misfolding.\",\n      \"evidence\": \"N-terminal sequencing of purified C1 from brain; in vitro peptide-PrPC mixing with ultracentrifugation, CD, and protease resistance readouts\",\n      \"pmids\": [\"7642585\", \"7479957\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the protease(s) performing α-cleavage in vivo not yet determined\", \"Whether α-cleavage actively protects against prion propagation in vivo untested\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrating that PrPC and PrPSc co-localize in caveolae-like raft domains—and that the N-terminal 49 residues are dispensable for scrapie susceptibility—established that raft microdomains are the conversion site and that PrP's C-terminal structured domain is sufficient for prion propagation.\",\n      \"evidence\": \"Detergent-resistant membrane fractionation in two species; transgenic PrP-null mouse rescue with N-terminally truncated PrP constructs\",\n      \"pmids\": [\"8962161\", \"8635458\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether raft disruption prevents conversion in vivo not tested\", \"Role of specific raft lipid species unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"The NMR solution structure of full-length human PrP and the discovery of caveolin-1/Fyn kinase signaling transformed understanding of PrPC from a passive substrate for conversion to a structured signaling protein whose globular domain interacts with its disordered N-terminal tail.\",\n      \"evidence\": \"NMR spectroscopy of recombinant PrP(23-230); antibody cross-linking Fyn activation assay in differentiated 1C11 neuronal cells\",\n      \"pmids\": [\"10618385\", \"10988071\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous PrPC ligands that trigger Fyn signaling unknown\", \"Whether N-terminal tail modulates signaling not tested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Three advances—atomic-resolution Cu²⁺ coordination in octapeptide repeats, identification of STI1 as a neuroprotective PrPC ligand, and demonstration that cytosolic PrP is acutely neurotoxic—revealed PrPC as a copper-binding signaling receptor with a misfolding-independent neurotoxic pathway when mislocalized to the cytosol.\",\n      \"evidence\": \"X-ray crystallography and EPR of HGGGW-Cu²⁺; GST pull-down and co-IP of PrPC-STI1 with apoptosis rescue; transgenic mice expressing cytosolic PrP with cerebellar degeneration\",\n      \"pmids\": [\"11900542\", \"12093732\", \"12386337\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Cu²⁺ binding is physiologically required for PrPC function in vivo unclear\", \"Mechanism of cytosolic PrP toxicity at the molecular level unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Anti-PrP antibody therapy dramatically prolonged survival in scrapie-infected mice by blocking cell-surface PrPC availability, directly proving that surface PrPC is the rate-limiting substrate for prion propagation and validating immunotherapy as a therapeutic strategy.\",\n      \"evidence\": \"Passive anti-PrP monoclonal antibody transfer in murine scrapie model with survival, PrPSc, and infectivity bioassays\",\n      \"pmids\": [\"12621436\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CNS penetration of antibodies not achieved\", \"Whether antibodies work post-clinical onset unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"The discovery that PrPC is a high-affinity receptor for Aβ oligomers—mediating LTP blockade that is absent in PrP-null mice—unexpectedly connected PrPC to Alzheimer's disease synaptotoxicity, expanding its pathological relevance beyond prion diseases.\",\n      \"evidence\": \"Expression cloning screen, surface plasmon resonance, hippocampal slice electrophysiology in wild-type and PrP-KO mice, anti-PrP antibody rescue\",\n      \"pmids\": [\"19242475\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding site on PrPC for Aβo not precisely mapped\", \"Whether PrPC-Aβo interaction occurs in human AD brain not directly shown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Elucidation of the downstream Aβo→PrPC→Fyn→NR2B phosphorylation cascade—causing NMDAR dysregulation, spine loss, and neuronal death—provided a complete signaling pathway linking PrPC to Alzheimer-type synaptic destruction.\",\n      \"evidence\": \"Co-IP, Fyn kinase assays, NMDAR surface biotinylation, spine imaging, PrP-null and Fyn-null mouse genetics\",\n      \"pmids\": [\"22820466\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Therapeutic efficacy of Fyn inhibition in AD models not tested in this study\", \"Contribution of this pathway relative to PrPC-independent Aβo toxicity unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of mGluR5 as the transmembrane co-receptor coupling extracellular PrPC-Aβo complexes to intracellular Fyn and Ca²⁺ signaling completed the receptor architecture and demonstrated pharmacological reversibility of cognitive deficits via mGluR5 antagonism.\",\n      \"evidence\": \"Reconstitution in Xenopus oocytes, co-IP of PrPC-mGluR5, Ca²⁺ imaging, behavioral rescue with mGluR5 antagonist in AD transgenic mice\",\n      \"pmids\": [\"24012003\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of PrPC-mGluR5 interaction unknown\", \"Whether mGluR5 antagonism is effective in human AD untested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrating that autophagy delivers misfolded PrP from the ER to lysosomes—and that autophagy inhibition increases protease-resistant PrP—identified autophagy as a cellular quality-control mechanism limiting PrPSc accumulation.\",\n      \"evidence\": \"Live-cell imaging of GFP-mutant PrP, ATG5-KO MEFs, 3-MA and rapamycin treatments with protease resistance readouts\",\n      \"pmids\": [\"24454378\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether autophagy induction clears PrPSc in vivo during active prion infection not tested\", \"Receptor(s) mediating selective PrP autophagy not identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapping three distinct ADAM protease α-cleavage sites near residue 109 and showing that the minimal lethal PrP deletion encompasses all three sites established α-cleavage as essential for limiting PrPC-intrinsic toxicity, with copper and zinc modulating cleavage efficiency.\",\n      \"evidence\": \"In vitro ADAM8/10/17 cleavage assays with recombinant PrP, metal modulation, correlation with published deletion mutant lethality data\",\n      \"pmids\": [\"24721836\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which ADAM protease is rate-limiting for α-cleavage in neurons not determined\", \"In vivo validation of copper/zinc modulation lacking\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Three convergent findings—that GPI-anchored raft association is required for persistent PrPSc propagation, that the native α-helical state kinetically inhibits amyloid formation, and that N-glycans at positions 181/197 sterically block aggregation—defined the biophysical constraints governing the conversion threshold.\",\n      \"evidence\": \"GPI vs. transmembrane PrP in prion-infected null cells; ThT kinetic assays with enzyme-kinetic modeling; semisynthetic PEG-glycan PrP aggregation assays\",\n      \"pmids\": [\"27847358\", \"28373719\", \"28989689\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether glycosylation-site occupancy varies in disease-affected brain regions unknown\", \"Kinetic model not validated with authentic brain-derived PrPSc seeds\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Complete prion resistance in PRNP-null goats after intracerebral inoculation—with dose-dependent delay in heterozygotes—provided definitive in vivo proof that PrPC expression level is the rate-limiting determinant of prion disease.\",\n      \"evidence\": \"Intracerebral scrapie inoculation of naturally occurring PRNP-null, heterozygous, and wild-type goats with IHC, EIA, and RT-QuIC\",\n      \"pmids\": [\"31924264\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PrPC ablation produces any long-term neurological deficits in goats not reported\", \"Applicability to human PRNP reduction strategies not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"The finding that creatine directly binds PrP and inhibits its Fe³⁺→Fe²⁺ reductase activity to confer ferroptosis resistance in endometriotic cells revealed an unanticipated iron-regulatory function for PrP outside the nervous system.\",\n      \"evidence\": \"DARTS target identification, cellular iron uptake assays, ferroptosis viability assays in patient-derived endometrial stromal cells\",\n      \"pmids\": [\"39119937\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of creatine-PrP binding unknown\", \"Whether PrP's iron reductase activity is relevant in neurons not established\", \"Single study requiring independent replication\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the high-resolution structure of infectious PrPSc, the identity of endogenous ligands that activate PrPC-Fyn signaling under physiological conditions, and whether therapeutic reduction of PrPC expression (e.g., ASO) can be tolerated long-term without compromising PrPC's neuroprotective and copper-trafficking functions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No atomic-resolution PrPSc structure available\", \"Physiological PrPC activating ligand unknown\", \"Long-term safety of PrPC depletion in humans untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [8, 14, 15, 16]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [10, 20, 28]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [22]},\n      {\"term_id\": \"GO:0140299\", \"supporting_discovery_ids\": [9, 27]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 8, 13, 17, 21, 24]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [19, 31]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 14, 15, 16]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [14, 15, 16]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [25, 26]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 2, 3, 4, 5, 18, 24, 30]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"FYN\",\n      \"CAV1\",\n      \"STIP1\",\n      \"GRM5\",\n      \"GRIN2B\",\n      \"ADAM10\",\n      \"ADAM17\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}